COMPREHENSIVE SPINOFF INVESTMENT OPPORTUNITIES

Upcoming Spinoffs Over Next 12 Months (September 2026 - September 2027)

Analysis Date: August 31, 2026 Pricing Date: All stock prices as of August 31, 2026 close (verified daily data via yfinance) unless otherwise noted.

EXECUTIVE SUMMARY: KEY CHANGES SINCE LAST REPORT (July 31, 2026)

Completed Since Last Report

Major Developments

• ⚠️ Honeywell Aerospace (HONA) broke — the largest single-name event in this report’s history. On August 6 HONA missed Q2 and cut guidance: organic sales growth to 4–5% from 7–9%, pro-forma standalone adjusted EBITDA to $4.35–4.45B from $4.65–4.75B, and 2026 adjusted EPS to $7.60–7.90 against an $8.86 consensus. Q2 sales were $4.5B (+5%) with adjusted EPS of $1.87 vs $2.75 a year earlier. Shares fell -23.1% in a single session to a post-spin low of $156.47 (day 38) and ended the month at $158.11, -23.5% for August and -28.2% vs the $220.19 Day-1 close. ⚠️ But management’s stated cause — a precision-casting supply crunch — is not the cause. Six years of Honeywell’s segment disclosure show margin falling in four consecutive periods, 27.7% → 24.5% → 23.6% in 1H26, 405 basis points, most of it before castings were mentioned. The driver is mix: Defense and Space went from 36.6% of segment sales in 2023 to 41.2% in 2025, and Honeywell paid $1.9B for CAES ten months before spinning the segment. Downgraded A (4.05) → B+ (3.20) — a two-notch cut driven by evidence that was always in the filings and had not been examined, not by the guidance cut. But the rating goes the other way: STRONG BUY → BUY, target $195. At 17.9x forward earnings against peers at 25–50x, with a bear case (margin flat forever) of ≈$163 and the stock at $158.11, a B+ business is trading at a C+ price. Full analysis in Part 3 §4.
• ⭐ Corteva/Vylor: the leverage question is answered, and the answer is benign. The August 14 Form 10-12B/A and the financings executed since disclose what July’s preliminary filing left blank. Vylor’s pro-forma balance sheet at June 30 carries $5,577M of total borrowings ($3,179M short-term, $2,398M long-term) against $1,100M of cash, with an estimated $3.56B cash distribution to New Corteva. Against FY2025 pro-forma operating EBITDA of $2,503M on ≈$9.9B of net sales (25.3% margin) that is 2.23x gross / 1.79x net leverage — moderate, and far from the debt-dumping pattern this report flagged at ADI Global. The financing is now executed, not hypothetical: $1.1B of new Vylor notes priced August 31 ($550M 5.125% due 2031, $550M 5.625% due 2036) and the exchange offers for EIDP’s notes drew $1,425M tendered at the August 19 early deadline (89.1%) with all requisite consents received. Grade A- (3.80) maintained and the “provisional” flag on Financial Profile is lifted. ⚠️ Still blank with four weeks to go: the record date, the distribution ratio and the ticker.
• ⭐ MSG Sports publicly filed the Rangers Form 10 on August 14 and set an end-of-October target. This name moves from “no timetable” to the second-most-imminent separation on the board. 1 MSGR share per 2 MSGS shares (both classes), tax-free, NYSE; MSG Sports is renamed MSG Knickerbockers (MSGK). The filing shows FY2026 pro-forma revenue of $341.5M, a pro-forma adjusted operating loss of $(16.3)M, and only $16.5M of debt. Upgraded C+ → B (2.60) — a trophy asset with a clean balance sheet, held back by losses, a Dolan dual-class structure and James Dolan serving as Executive Chairman and CEO of both successors.
• ⭐ Solstice (SOLS) and Element Solutions terminated their merger on August 27 — the July downgrade reverses. Both boards concluded the companies serve shareholders better standalone; no break fees either way. Solstice paired the termination with a $500M buyback and shares rose +12.8% on the news. The security is once again the clean, high-margin specialty-materials pure-play this report graded, with FY guidance raised in July (revenue $4.13–4.19B, adjusted EBITDA $1.04–1.06B). Solstice takes a first investment grade of A- (3.63) on a franchise that includes a duopoly in HFO-1234yf and the only US uranium hexafluoride conversion capacity. The rating stays HOLD, target $62 — the termination was the upside case standalone analysis had identified, and the market paid for it the same day. At $63.39 against a standalone fair value of ≈$61 (range $55–69) and ≈11.2x EV/EBITDA, the value has been collected rather than created.
• Mobility Global (MBGL) delivered its first standalone quarter and the numbers validate July’s corrected figures. Q2: revenue $468M (+7%), CARFAX $312M (+8%), adjusted EBITDA $202M — a 43% margin, net income $53M, diluted EPS $0.18, free cash flow $129M. FY26 guidance: revenue $1,870–1,885M, adjusted EBITDA $745–760M (≈40% margin). The board declared a first quarterly dividend of $0.06/share — $0.24 annualized, a 1.18% yield, roughly double this report’s July estimate. Grade A maintained; BUY at 10.2–10.5x FY26E EV/EBITDA. One correction to July’s model is required: 1H26 free cash flow of $177M is down ≈20% year over year on $57M of separation costs, well below the ≈$500M full-year run-rate this report projected.
• Barrick cleared the last structural obstacle to the North American gold IPO. On August 9 Barrick and Newmont agreed to expand the Nevada Gold Mines JV — Barrick contributes Fourmile, Newmont contributes Mike and Fiberline, and Newmont pays Barrick a $1.95B cash top-up — resolving all outstanding JV disputes and securing Newmont’s consent for the IPO. CEO Mark Hill named; on track by year-end. Shares +22.1% in August. Upgraded B → B+ (3.25) — the 10–15% float remains the cap on the grade.
• Modine/Gentherm cleared its regulatory gate. The Form S-4 was declared effective August 12 and the proxy mailed; the Gentherm special meeting is September 10, 2026 and is the only remaining shareholder approval. Close expected by year-end 2026. Upgraded B → B+ (3.20).
• ⚠️ Resideo (REZI) fell -26.0% from its first ex-distribution close — the worst tracked parent debut. Q2 beat (record $1.98B revenue, $0.83 adjusted EPS) but the initiation of standalone guidance on August 12 reset FY26 revenue to $2.90–2.95B and cut adjusted EPS guidance ≈6.8% to a $2.62 midpoint. Shares fell 19.3% on August 13.
• ⚠️ Aptiv (APTV) fell -20.7% in August and -42.4% since the Versigent spin, on a 2026 guidance cut (revenue midpoint down $300M to $12.6–12.8B, EBITDA down ≈3% for the year and ≈7% in 2H) citing China weakness and program-launch delays. Deutsche Bank and Morgan Stanley both downgraded. Meanwhile SpinCo Versigent (VGNT) rose +14.6% on a strong Q2 (net sales $2,444M +10.8%, adjusted EBITDA $272M +24.8%). The SpinCo/RemainCo gap here is now +70.2% vs -42.4% — the widest in the dataset.
• Atrium Therapeutics (RNA) finally has a fundamental catalyst. FDA cleared the IND for ATR-1072, the Corventis Phase 1/2 trial launched (the first study of a potential disease-modifying treatment for PRKAG2 syndrome), and a second BMS milestone triggered a $15M payment in August. Cash of $263.9M at June 30. +17.4%, the best performer of the month among names graded before the fact (Sandisk’s +29.0% is a memory-cycle move on a name added to coverage this edition), and the first evidence against this report’s “pre-acquisition spins never snap back” pattern.
• ⚠️ Keurig Dr Pepper still has no Global Coffee CEO. Q2 (August 6) beat on EPS ($0.57 vs $0.54) and reaffirmed guidance, but the search Pamela Patsley opened in June remains unresolved two months on. Separation still targeted early 2027 with operational readiness by year-end 2026. B (2.95) maintained.
• ⚠️ FedEx Freight (FDXF) downgraded A- (3.80) → B+ (3.15); rating BUY → HOLD, target $108. Two primary documents landed this month that post-date the last grade — the FY2026 Form 10-K (August 5) and the calendar-year 2025/2024 recast (August 6) — and they supply nine years of operating-ratio history the pre-spin grade never had. The adjusted operating ratio is 88.3% against 80.0% at the FY2023–24 peak, but the long record shows the peak was the anomaly: FDXF ran 87.2–93.9% in the five years before FY2022. Mid-cycle is 85%, not 82.5% — worth about $15 a share. Volumes are -4% (and -24% from the FY2019 peak), and reported earnings contain $373M of related-party interest income that ends at separation. At 16.3x trailing EBITDA against a 15.2x peer median with the group’s highest leverage, the spinoff discount this report has been waiting to buy was never there.
• 🆕 Two long-completed separations are added to Part 3 coverage this edition: Ralliant (RAL) and Sandisk (SNDK). Both separated inside the window Part 3 already covers — Fortive → Ralliant on June 30, 2025 and Western Digital → Sandisk on February 24, 2025 — and both now carry enough disclosure to grade. Ralliant: A- (3.50), HOLD, target $58 — an excellent Sensors franchise (28.4% margins) stapled to a Test & Measurement business earning 2.4% after a $1.44B impairment, at 30.9x earnings. Sandisk: B (2.93), HOLD, no target — +3,123.7% since its spin, the largest outcome in the tracked set, on a NAND pricing cycle in which 91% of FY2026’s 175% revenue growth was price. Neither addition reflects a new event; both close a coverage gap.
• ⚠️ Medtronic softened the MiniMed timing. Q1 FY27 (August) reaffirmed the separation but framed it as “before fiscal year-end” — i.e. by April 2027, rather than the year-end 2026 previously guided — and “when the economics are optimal.” MMED rose +12.2% and closed above its $20 IPO price for the first time. B- maintained.
• Qnity (Q) beat enormously and fell anyway. Q2 (August 4): net sales $1.4B (+22%), adjusted EPS $1.19 against a $0.65 consensus, ninth consecutive quarter of profitable growth, FY guidance raised to $5.55–5.65B revenue / $1.675–1.725B adjusted EBITDA / $4.40–4.60 EPS. The stock popped to $142.59 and then faded to $119.43, -9.0% for the month — every dollar of the 32% decline from the June high is multiple compression. ⚠️ But the filings narrow the thesis. Qnity’s own disclosure shows realised price falling 1–2% a year in both segments in both 2024 and 2025 — the two strongest years the industry has ever had — and four-year segment margin is flat (31.3% in 2022, 31.2% in 2025) with 1.7x downside operating leverage demonstrated in 2023. Grade trimmed A- (3.80) → A- (3.58), band unchanged; rating cut BUY → HOLD, target $132, accumulate below ≈$115. The growth is volume, not price, and that cuts both ways.

NEW Spinoffs Added to Tracking

Removed / Status Changed

• ADIG: Completed August 3–4; moved to Part 3 tracking.
• ⬇️ Honeywell Aerospace (HONA): Downgraded A (4.05) → B+ (3.20) on six years of segment history, not on the guidance cut; rating STRONG BUY → BUY, target $195.
• ⬇️ FedEx Freight (FDXF): Downgraded A- (3.80) → B+ (3.15) on the FY2026 10-K and calendar-year recast; rating BUY → HOLD, target $108.
• ⬇️ Qnity (Q): grade trimmed A- (3.80) → A- (3.58) on the pricing decomposition; rating BUY → HOLD, target $132.
• 🆕 Solstice (SOLS): merger terminated August 27; first grade A- (3.63); rating HOLD, target $62.
• 🆕 Versigent (VGNT): first grade B+ (3.20); rating BUY, target $62.
• 🆕 Ralliant (RAL) and Sandisk (SNDK) added to Part 3 tracking with first grades of A- (3.50) and B (2.93); both HOLD.
• ⬆️ MSG Sports → MSG Rangers (MSGR): C+ → B; Form 10 public August 14, target end-October 2026, ticker and ratio set.
• ⬆️ Barrick → North American Barrick: B → B+ on the Newmont settlement and IPO consent.
• ⬆️ Modine/Gentherm → Performance Technologies: B → B+ on S-4 effectiveness and a set vote date.
• ⬆️ Octave Intelligence (OCTV): rating HOLD → BUY — the higher low this report was waiting for has been confirmed.
• ⚠️ Medtronic → MiniMed: timing loosened from “year-end 2026” to “before fiscal year-end” (April 2027).
• ⚠️ J&J → DePuy Synthes: the spin-vs-sale decision is now roughly three months past the mid-2026 guidance with no announcement. B maintained, decision flagged overdue for a second consecutive report.
• ⚠️ KBR → Trinzic: date reaffirmed January 4, 2027, but no Form 10 has been filed — an EDGAR full-text search for “Trinzic” returns no registration statement as of August 31, four months from distribution. B+ maintained, filing flagged as the gating item.
• ⚠️ Unilever → Foods/McCormick: the CMA’s invitation to comment closed August 5, but the regulator has not yet formally commenced a Phase 1 investigation. Unilever is carving out Colman’s ahead of the deal. B maintained.
• ABVC BioPharma → BioKey: distribution was slated for ≈August 3; no completion announcement could be located as of the pricing date. Carried as a footnote with status unconfirmed.
• New Fortress Energy → BrazilCo/CoreCo: no completion confirmed; the Q3 2026 target now looks unlikely to be met. C maintained.
• Flex → SpinCo: leadership named July 29 (Revathi Advaithi to SpinCo, Michael Hartung to Flex), but the SpinCo name promised for September has not been unveiled. FLEX itself is -32.6% since June 30 on the semiconductor de-rating. B maintained.
• Kraft Heinz (paused), Teleflex (converted to sales), Microsoft → Xbox (rumor/under review): unchanged, not tracked as active spins.
• Not individually tracked (non-US or pre-announcement): SoftBank → Roze, Associated British Foods → Primark, Siemens Energy → Industrial Turbines, Baidu → Kunlunxin, Jollibee → International, Evotec → Just Biologics, Alibaba (HKEX-approved spin), UPM-Kymmene → WISA.

Part 1: Upcoming Spinoffs Overview (Next 12 Months)

IMMEDIATE OPPORTUNITIES (Next 30 Days)

Sort: within bucket, by investment grade (highest first).

Q4 2026 SPINOFFS (Oct–Dec)

Q1 2027 SPINOFFS (Jan–Mar)

Q2–Q4 2027 SPINOFFS (Approaching / Just Beyond the 12-Month Window)

Sort: within bucket, by investment grade (highest first); ties broken by the Part 2 ranking.

EXPLORATORY / UNCERTAIN TIMING

Summary: 26 active separations tracked over the next 12–15 months after one completion this cycle (ADIG) and one new large-cap addition (Solventum). The calendar has re-densified around Q4 2026: Corteva/Vylor on October 1, MSG Rangers by end-October, Modine/Gentherm by year-end after its September 10 vote, and Barrick’s North American IPO before December. Largest by revenue: Comcast/NBCUniversal (≈$40B+), KDP Global Coffee (≈$16B), McKesson Med-Surg ($11.4B), Eaton/Dana combined (≈$11B), Corteva ($9.9B seed + $7.8B crop protection). Highest quality: Corteva → Vylor (A-), unchanged as the top-graded upcoming name and now graded on disclosed rather than assumed leverage. The month’s trend reversed July’s: three upgrades against zero downgrades among upcoming names, driven by documents actually filed — a Form 10/A, a Form 10, an effective S-4 and a JV settlement.

Part 2: In-Depth Analysis (Top-Tier & Imminent)

Upcoming Spinoffs — Ranked by Grade

All tracked upcoming separations, ranked by investment grade. Score is the weighted scorecard value (shown for the deep-dived names); ★ is the quick visual tier mapped from grade.

Micro-cap footnotes not ranked: ABVC → BioKey (status unconfirmed), Jet.AI → DCTR, Vivani → Cortigent, Click Holdings → Logistics. Non-US monitored only: UPM-Kymmene → WISA.

Sort: by investment grade / weighted score, highest first. Ties broken by transaction size. Completed name (ADIG) moved to Part 3.

Deep-dive roster note: the six deep-dives below are the five highest-graded upcoming names plus MSG Rangers, promoted on imminence — it is the second transaction to distribute in this window (end of October) and its Form 10 became public this cycle. Keurig Dr Pepper drops out of the deep-dive set for the first time; with no CEO named and no separation date, there is nothing new to underwrite. Deep-dives run in ranked order, with the promoted name last.

1. Corteva → Vylor (Seed) / New Corteva

Executive Summary

• Company: Corteva, Inc. (CTVA) — Current Price: $84.63 (Aug 31, 2026), +7.5% in August
• SpinCo: Vylor, Inc. (Seed) — spun from New Corteva (Crop Protection)
• Industry: Agricultural Inputs — Expected Completion: October 1, 2026
• Structure: Classic Spinoff — Investment Grade: A- (Strong Opportunity)
• Key Thesis: Still the highest-graded name on the upcoming board, and for the first time it is graded on disclosed leverage rather than an assumption. The August 14 amendment and the financings executed since show a SpinCo levered at 2.23x gross / 1.79x net on a 25.3% EBITDA margin — a normal separation capital structure, not a debt dump. The sitting Corteva CEO moving to Seed remains the strongest single signal that Vylor is the crown jewel.

Transaction Overview

• SpinCo (Vylor): Seed and genetics — Pioneer germplasm, traits and licensing; $9.9B of FY2025 net sales, sold in more than 70 countries. Leader by revenue share in North America corn and soybeans, Europe corn and sunflower, and Brazil, India, South Africa and Argentina corn. CEO Chuck Magro; Independent Chair Karen Grimes (ex-Wellington)
• RemainCo (New Corteva): Crop protection chemistry and biologicals; ≈$7.8B revenue. CEO Luke Kissam
• Rationale: Seed and crop protection have divergent capital intensity, R&D cycles and margin structures; separation lets each be valued on its own terms
• Filing note: For accounting purposes Corteva’s Crop Protection Business is presented as being spun off from Corteva, with Vylor as the continuing registrant — a presentation the filing attributes to “Vylor’s relative significance to New Corteva.” Compare historical financials with that in mind

What the amended Form 10 finally disclosed

The June 29 Form 10-12B left Vylor’s debt, its cash distribution to EIDP, the distribution ratio and the record date as blank placeholders. This report flagged that amendment as “the single most important document pending on this name.” It was filed August 14, 2026, and the pro-forma financial statements answer the leverage question:

⚠️ The filing carries two different debt figures, and they are not interchangeable. The Article 11 pro-forma balance sheet is struck at June 30, 2026; the “Sources and Uses of Capital” section presents management’s estimate of expected balances at the October 1 closing date. The filing states explicitly that the two “are not directly comparable and will differ, including as a result of seasonal working capital.” Both are shown below; the October 1 column is the decision-relevant one.

Leverage: 2.23x gross, 1.79x net on FY2025 pro-forma operating EBITDA — or 1.63x net against an FY2026E EBITDA of roughly $2.75B. Both are struck at a seasonal peak in borrowings, and Vylor targets an investment-grade rating. For comparison, this report’s two most recent debt-loading cases were Mobility Global at 2.81x gross (above its own <2.5x target on day one) and ADI Global at 3.14x on a 6.6% margin. Vylor levers up to pay the parent — the mechanism this report identified in June — but the magnitude is ordinary, and a 25.3% EBITDA margin comfortably services it. Note that the $3,179M of short-term borrowings reflects a seed business’s seasonal working capital, and the filing warns the June 30 snapshot understates working capital versus the actual October 1 spin date.

The financing is executed, not hypothetical. Three facts changed between the amendment and the pricing date:

1. Exchange offers: Vylor offered to exchange EIDP’s 2.300% notes due 2030, 5.125% due 2032 and 4.800% due 2033 ($1.6B outstanding) for corresponding Vylor notes. At the August 19 early-tender deadline, $1,425M (89.1%) had been tendered — above the 80% the pro formas assumed — and all requisite consents to strip the EIDP indenture covenants were received. Expiration extended to September 29, 2026.
2. New notes priced: on August 31 Vylor issued $550M of 5.125% Senior Notes due 2031 and $550M of 5.625% Senior Notes due 2036 under a purchase agreement dated August 20, with Morgan Stanley, J.P. Morgan and BofA as representatives. ⚠️ Note the cost of debt this implies. The exchanged EIDP notes carry a 4.12% weighted average; the new money priced at 5.125–5.625%. The pro formas were built before either was known, so Vylor’s blended coupon will run above the 4.12% the exchanged paper alone suggests — the quantum of debt is settled, its cost is at the higher end of what the filing assumed.
3. Backstops in place: a $3.0B Five-Year Revolving Credit Facility, a $1.5B 364-Day Revolving Credit Facility, a Delayed Draw Term Facility of up to $2,750M (reduced dollar-for-dollar by notes issued), a $3.5B Commercial Paper Program effective post-spin, and a PHI Bilateral Facility running September 1 to October 1 as a bridge.

⚠️ What is still not disclosed

The amendment fills the two blanks that matter most and leaves five. Two of the remainder carry real consequence beyond mechanics:

• Dividend policy is a valuation input. The filing says only that combined Vylor and New Corteva dividends, if any, will equal Corteva’s pre-spin annual dividend — how that splits is unstated.
• The “Applicable Percentage” governs how shared environmental and legacy liabilities that cannot be assigned to either business are split between the two companies. It matters more than its name suggests: it sits at the end of an indemnification chain that runs from Chemours’ balance sheet, through New Corteva’s indemnification assets, to Vylor’s PFAS exposure.

With four weeks to the October 1 target, an investor still cannot know the date by which they must own CTVA. The September 29 exchange expiration is consistent with an October 1 close and Corteva has reaffirmed the date at every opportunity — but the mechanics announcement is now the gating event, and its absence is why this name is not upgraded despite good news on leverage.

Key Developments Since Last Report

• Aug 6: Exchange offer memorandum issued for the EIDP notes
• Aug 14: Form 10-12B/A filed with pro-forma financials, capitalization and the description of material indebtedness
• Aug 19–20: Early tender results — $1,425M (89.1%) tendered against the 80% the pro formas assumed, requisite consents obtained; expiration extended to September 29. Higher take-up shifts the Vylor/EIDP debt mix, not the total
• Aug 31: $1.1B of new Vylor senior notes issued (5.125% 2031 / 5.625% 2036); registration rights agreement executed
• CTVA shares +7.5% in August to $84.63, recovering the July 31 drop

Investment Scorecard

Grade Change: A- (3.80) maintained — and the provisional flag is lifted. The trigger is the arrival of the document this report named as decisive. Financial Profile stays at 4, but for a different reason: in July it was a 4 despite missing the leverage input; it is now a 4 because the disclosed leverage is moderate and the margin is a genuine 25.3%. Had Vylor come in above 3x on a sub-15% margin, the ADI Global precedent says this would have been a downgrade. It did not. A new flag replaces the old one: the record date and ratio are unset with four weeks to go.

What the grade is not saying is that the stock is cheap. A- is a judgment on transaction quality — a clean two-way separation, the good assets and the entire incumbent C-suite on one side, the legacy history on the other, moderate leverage, and a coherent strategic reason for each half to exist. On price, Corteva has already captured most of the re-rating: the shares are +7.5% in August and within 5% of their level before the separation was announced. The asset is excellent; the entry is not obviously attractive. Both belong on the page.

Recommendation: ⭐⭐⭐⭐ OWN CTVA INTO THE RECORD DATE to receive both entities — there is no cost to participating and the transaction quality is the highest on the board. This is a participation call, not a valuation call; investors underwriting Vylor on price rather than on receipt should wait for the post-spin trading window. Next catalysts: the record-date announcement, which on an October 1 distribution should arrive in the first half of September — if it has not appeared by mid-September, treat that as evidence the date is slipping — and the S&P index decision on Vylor, which is announced in advance and determines whether a forced-selling flush happens at all.

Acquisition Analysis (SpinCo)

Potential Acquirers: Limited by scale and antitrust. Bayer Crop Science and Syngenta/ChemChina are the only strategic fits for Vylor’s germplasm and both face insurmountable overlap review. Large-cap PE consortia could pursue New Corteva’s crop-protection assets, which are more divisible. Acquisition Likelihood: Low for Vylor, Low-Medium for New Corteva. Impact on Thesis: Acquisition is not the thesis here — the value case is the re-rating of two focused ag businesses out of a conglomerate multiple.

Sources

• SEC — Vylor Form 10-12B/A information statement (August 14, 2026)
• SEC — Corteva 8-K: early tender results and extension of the Vylor exchange offers (August 20, 2026)
• SEC — Corteva/EIDP 8-K: Vylor $1.1B notes offering (August 31, 2026)
• PR Newswire — Corteva 1H 2026 results, raised FY outlook, on track for October 1 separation

2. Comcast → NBCUniversal

Executive Summary

• Company: Comcast Corporation (CMCSA) — Current Price: $26.62 (Aug 31, 2026), +11.1% in August
• SpinCo: NBCUniversal (including Sky) — Universal theme parks and studios, NBC broadcast, Peacock, Sky
• Industry: Media & Entertainment — Expected Completion: ≈Mid-2027
• Structure: Classic Spinoff · Retained Stake — Investment Grade: B+ (Solid Opportunity)
• Key Thesis: The largest separation on the board by revenue, but ten months out with no Form 10, no ticker and an explicit intention by Comcast to retain up to 19.9% for up to a year.

Transaction Overview

• SpinCo (NBCUniversal): Universal Destinations & Experiences, Universal Pictures, NBC, Peacock, Sky; ≈$40B+ of revenue. CEO Mike Cavanagh
• RemainCo (Comcast): Broadband, wireless, business services — the connectivity and platform business
• Rationale: Separate a capital-intensive, cyclical media and experiences business from a subscription connectivity utility so each can be valued and capitalised on its own terms
• ⚠️ Retained stake: Comcast expects to retain up to 19.9% of the SpinCo for up to one year

Key Developments Since Last Report

• No new company disclosure in August. The Form 10 remains unfiled and no distribution mechanics have been set.
• The read-across improved materially. Versant (VSNT) — Comcast’s January cable-networks carve-out and the best available proxy for how this market prices Comcast media assets — rose +14.3% in August to $41.12, cutting its deficit versus Day 1 from -20.3% to -9.0% and putting it +50.0% above its post-spin low. Q2 (August 6) showed 120M+ monthly viewers and growth in the platforms business (Fandango, GolfNow, and the newly acquired Full Swing). A market that was pricing Comcast’s media assets for terminal decline in February is no longer doing so.
• CMCSA itself rose +11.1% in August, narrowing its post-Versant decline to -4.2%.

Investment Scorecard

Grade Change: B+ (3.40) maintained, unchanged. No company disclosure arrived in August. The Versant recovery is encouraging for the eventual valuation but is a read-across, not a fact about NBCUniversal, and under this report’s sourcing discipline a proxy asset’s share price does not move a scorecard dimension.

Recommendation: ⭐⭐⭐ MONITOR — still too early to position. Distribution is ≈10 months away, so there is no record date to own CMCSA into. Reassess on the Form 10 and, critically, on whether the up-to-19.9% retained stake is reduced or eliminated before distribution — the single change that would move this score up.

Acquisition Analysis (SpinCo)

Potential Acquirers: At ≈$40B+ of revenue, NBCUniversal is acquirable only by a handful of parties — Netflix (regulatorily implausible for the broadcast assets), Amazon or Apple (balance-sheet capable, parks are a poor fit), or a sovereign/PE consortium for the parks alone. Acquisition Likelihood: Low as a whole; Medium for piecewise divestiture of Sky or the cable-adjacent assets post-spin. Impact on Thesis: Minimal — this is a value-unlock story, not a takeout story.

Sources

• CNBC — Comcast to spin off NBCUniversal and Sky from cable business
• BusinessWire — Comcast announces plans to separate media and technology businesses
• CNBC — Versant (VSNT) Q2 2026 results

3. KBR → Trinzic

Executive Summary

• Company: KBR, Inc. (KBR) — Current Price: $37.50 (Aug 31, 2026), +2.4% in August
• SpinCo: Trinzic — Mission Technology Solutions (defense, space and intelligence services)
• Industry: Government Services / Defense Technology — Expected Completion: January 4, 2027
• Structure: Classic Spinoff — Investment Grade: B+ (Solid Opportunity)
• Key Thesis: A ≈$5.8B-revenue federal services business separating from an asset-light technology licensor, with a firm date, a full C-suite and improving margins — but, four months out, no registration statement on file.

Transaction Overview

• SpinCo (Trinzic): KBR’s Mission Technology Solutions segment — ≈$5.8B revenue, ≈20,000 employees. CEO-designate Michael LaRouche (ex-Serco North America); CFO named June 25
• RemainCo (KBR): Sustainable Technology Solutions — process technology licensing, catalysts, and energy-transition engineering; an asset-light, higher-margin business
• Rationale: Multiple arbitrage. Federal services trades at services multiples; technology licensing trades at technology multiples. Holding both suppresses the latter
• Structure: Tax-free to KBR and its shareholders for US federal income tax purposes; distribution on the first business day of KBR’s 2027 fiscal year

Financial Structure (H1 2026, from KBR’s Q2 disclosure)

The margin split is the whole thesis in one table: Trinzic is twice RemainCo’s size and earns barely more EBITDA. Separately valued, an 11–12% margin services business and a 20% margin licensing business should not carry the same multiple.

Key Developments Since Last Report

• Aug 10: Trinzic secured an estimated $208M cost-plus-fixed-fee task order to continue supporting the US Army’s Tactical Aviation and Ground Munitions (TAGM) portfolio
• Aug 18: KBR publicly reaffirmed January 4, 2027 as the separation date
• Q2 spin-off costs of $31M ($46M for the half year)
• ⚠️ No Form 10 registration statement has been filed. An EDGAR full-text search for “Trinzic” returns no registration statement as of August 31. On a January 4 distribution, a Form 10 would ordinarily be public by now; it is the gating item and its absence is the single largest risk to the date

Investment Scorecard

Grade Change: B+ (3.40) maintained. August brought a contract win and a date reaffirmation, neither of which moves a dimension. The Financial Profile score of 3 is now anchored to a disclosed 11.4% margin rather than a sector generalisation, which is a firmer 3 than July’s — but it is still a 3, and the absence of a Form 10 means the separation debt, the share count and the distribution ratio remain entirely unknown. Under this report’s sourcing standard, a name four months from distribution with no registration statement cannot be upgraded.

Recommendation: ⭐⭐⭐ ACCUMULATE KBR ahead of the record date (expect ≈December 2026). Trinzic’s services profile is unlikely to re-rate dramatically; the more interesting post-spin security may be RemainCo KBR as an asset-light technology licensor at a 20% margin. Watch for the Form 10 — if it has not appeared by early October, the January 4 date is in question.

Acquisition Analysis (SpinCo)

Potential Acquirers:

1. Leidos (LDOS) — the natural consolidator in federal IT/mission services; overlapping customer sets and clear cost synergies. LDOS is +21.3% in August and has the currency
2. Amentum (AMTM) — itself a recent spin-merge; scale-driven strategy makes Trinzic a fit
3. PE (Veritas Capital, Arlington Capital) — both specialize in carving and recombining federal services assets

Acquisition Likelihood: Medium — federal services consolidates continuously, and a clean SpinCo with no parent stake is an easy target. Regulatory barriers are low; the constraint is organic-conflict and recompete risk. Estimated Timeline: 12–24 months post-spin (i.e., 2028). Impact on Thesis: A meaningful secondary support to the valuation floor.

Sources

• StockSpinoffs — KBR sets January 4, 2027 for the Trinzic spinoff (August 18, 2026)
• GlobeNewswire — KBR awarded $208M Army contract to advance next-generation tactical munitions (August 10, 2026)
• SEC — KBR Form 8-K, Q2 2026 results

4. Barrick → North American Barrick — ⬆️ Upgraded on the Newmont settlement

Executive Summary

• Company: Barrick Mining Corporation (B) — Current Price: $44.83 (Aug 31, 2026), +22.1% in August
• SpinCo: North American Barrick — four Tier One gold assets
• Industry: Gold Mining — Expected Completion: by year-end 2026
• Structure: IPO Carve-Out · Retained Stake — Investment Grade: B+ (Solid Opportunity) ⬆️ (from B)
• Key Thesis: August removed the structural obstacle that had kept this transaction theoretical. The remaining constraint is not legal or operational — it is that only 10–15% will be floated.

Transaction Overview

• SpinCo (North American Barrick): Carlin, Cortez and Turquoise Ridge (within the Nevada Gold Mines complex) plus Pueblo Viejo in the Dominican Republic — four Tier One assets, ≈$5.2B of revenue. CEO Mark Hill
• RemainCo (Barrick): Africa, Latin America (ex-Pueblo Viejo) and Asia-Pacific gold and copper, including Reko Diq and Lumwana
• Listing: NYSE primary, TSX secondary
• ⚠️ Float: only 10–15% to be sold; Barrick retains 85–90%

The Newmont agreement — what changed on August 9

The Nevada Gold Mines joint venture with Newmont was the structural problem: Barrick could not cleanly carve out Nevada assets it co-owns without its partner’s cooperation, and the two had unresolved disputes over the JV and over the timing of Fourmile, Barrick’s high-grade adjacent deposit. The August 9 agreement resolves all of it in one transaction:

• Barrick contributes Fourmile into NGM; Newmont contributes Mike and Fiberline
• Newmont pays Barrick a $1.95B cash top-up
• All outstanding NGM disputes are settled and the JV agreement is revised
• Newmont consents to the IPO of Barrick’s North American gold assets

That last point is the one that matters for this report. The transaction now has a clear path; shares rose 22.1% in August, and part of that is the market marking the separation from “announced” to “happening.”

Key Developments Since Last Report

• Aug 9: Newmont agreement — Fourmile into NGM, $1.95B top-up to Barrick, all disputes settled, IPO consent secured
• Aug 10: Q2 results missed profit estimates; the Nevada settlement dominated the reaction
• Executive team dedicated to the entity confirmed, with Mark Hill as CEO upon separation
• IPO reaffirmed for year-end 2026

Investment Scorecard

Grade Change: Upgraded B (est. 2.85) → B+ (3.25). Trigger: the August 9 Newmont agreement, which secured IPO consent, settled every outstanding JV dispute and delivered $1.95B of cash. Strategic Rationale moves 3 → 4 because the transaction is now executable rather than contingent on a counterparty’s cooperation. The grade does not go higher because of the float: at 10–15%, this is a valuation-marking exercise, not a separation. The MiniMed precedent in this report’s own tracking — a ≈90% retained stake, a stock below its IPO price for five months — is the direct analogue.

Recommendation: ⭐⭐⭐ OWN THE PARENT, NOT THE FLOAT. Barrick (B) captures the $1.95B settlement, the re-rating of the Nevada position and 85–90% of whatever the SpinCo is valued at, without the thin-float mechanics. Revisit the SpinCo only if Barrick commits to a schedule for distributing the remaining stake — that commitment, not the IPO itself, is the value event.

Acquisition Analysis (SpinCo)

Potential Acquirers: Newmont (NEM) is the only party with the assets, the balance sheet and the JV position to make a combination logical — and it has just spent $1.95B settling into a partnership instead. Agnico Eagle and Kinross are credible North American consolidators but could not absorb four Tier One assets at this scale. Acquisition Likelihood: Very Low while Barrick retains 85–90%. Estimated Timeline: Not applicable until the retained stake is distributed. Impact on Thesis: None. This is a sum-of-the-parts and jurisdictional-discount story, not a takeout story.

Sources

• Barrick — Advances IPO of North American gold assets, announces executive appointments
• BNN Bloomberg — Barrick misses Q2 profit estimates, settles Nevada dispute with Newmont (August 10, 2026)
• SEC — Barrick Mining Form 6-K

5. Modine / Gentherm → Performance Technologies (RMT) — ⬆️ Upgraded on S-4 effectiveness

Executive Summary

• Companies: Modine Manufacturing (MOD) $178.43, -11.3% in August · Gentherm (THRM) $39.29, -3.2% in August
• SpinCo: Modine’s Performance Technologies business, combining immediately with Gentherm
• Industry: Thermal Management — Expected Completion: by year-end 2026
• Structure: Reverse Morris Trust — Investment Grade: B+ (Solid Opportunity) ⬆️ (from B)
• Key Thesis: The regulatory gate that held this at B for three consecutive reports has cleared. The interesting security may be RemainCo Modine, which becomes a pure-play climate-solutions company with data-center cooling exposure.

Transaction Overview

• SpinCo (Performance Technologies): Modine’s vehicular thermal-management business — powertrain cooling, heat exchangers and related components
• Combining with: Gentherm (THRM), the thermal comfort and pneumatic-comfort supplier; Gentherm targets ≈$3.5B of combined revenue
• RemainCo (Modine): Climate Solutions — HVAC, heat transfer and data-center cooling, the segment carrying the growth narrative
• Transaction value: ≈$1.0B; ≈$2.6B of combined revenue
• Rationale: Modine sheds a cyclical, auto-exposed business to become a pure-play climate/thermal company; Gentherm gains scale beyond automotive seating comfort

Key Developments Since Last Report

• ✅ Aug 12: the Form S-4 was declared effective by the SEC, and the definitive proxy statement/prospectus was mailed to Gentherm shareholders on or about the same day. In July this report flagged that “no securities may be issued or transferred until they are” — that condition is satisfied
• Sept 10, 2026: Gentherm special meeting to vote on the Share Issuance Proposal and the Charter Amendment Proposal. These are the only Gentherm shareholder approvals required for completion
• Aug 20: Modine held its annual meeting (routine business; no transaction items)
• Close still expected by the end of calendar 2026, subject to the vote, SpinCo financing, an IRS ruling and regulatory clearances

Investment Scorecard

Grade Change: Upgraded B (est. 2.90) → B+ (3.20). Trigger: S-4 effectiveness on August 12 and a set shareholder vote on September 10. Strategic Rationale moves 3 → 4 as the Modine pure-play thesis firms up alongside execution certainty. The grade is capped at B+ because the SpinCo’s own margins and separation debt are still not separately disclosed — under this report’s standard, an RMT that presents only combined pro-formas leaves the most important number (what debt travels with the spun business) unanswered.

Recommendation: ⭐⭐⭐ PREFER MODINE (MOD) OVER GENTHERM (THRM). Modine is down 33.2% from its June 30 level and, post-close, becomes a pure-play climate-solutions company at a point when data-center cooling demand is the most durable industrial end-market available. Gentherm holders are voting to issue shares to acquire a cyclical auto business. The September 10 vote is the near-term binary.

Acquisition Analysis (SpinCo)

Potential Acquirers: Dana (now committed to the Eaton Mobility RMT), BorgWarner, Valeo and Mahle all have overlapping thermal portfolios; Hanon Systems’ owners have been a recurring seller/consolidator in the space. Acquisition Likelihood: Medium at 12–24 months post-close, once the combination is integrated and the pro-forma margin profile is visible. Impact on Thesis: Secondary. The primary case is the Modine re-rating.

Sources

• Modine — Gentherm and Modine’s Performance Technologies business to combine
• SEC — Gentherm Form S-4
• StockTitan — Gentherm S-4/A: Modine Performance Technologies merger details

6. MSG Sports → MSG Rangers (MSGR) — ⬆️ Upgraded; ⚠️ distributes end-October (promoted on imminence)

Executive Summary

• Company: Madison Square Garden Sports Corp. (MSGS) — Current Price: $384.73 (Aug 31, 2026), -2.3% in August
• SpinCo: MSG Rangers Corp. (MSGR) — the New York Rangers, the Hartford Wolf Pack (AHL) and the MSG Training Center
• RemainCo: MSG Knickerbockers Corp. (MSGK) — the New York Knicks and the Westchester Knicks
• Industry: Professional Sports — Expected Completion: end of October 2026
• Structure: Classic Spinoff · Dual-Class — Investment Grade: B (Moderate / Hold) ⬆️ (from C+)
• Key Thesis: A scarce trophy asset with essentially no debt, separating on a firm-ish near-term timetable — and a governance structure that gives minority holders very little say in what happens to it.

Transaction Overview

• SpinCo (MSG Rangers Corp.): New York Rangers (NHL), Hartford Wolf Pack (AHL), MSG Training Center. NYSE: MSGR (Class A); Class B will not be listed
• RemainCo (MSG Knickerbockers Corp.): New York Knicks (NBA), Westchester Knicks (G League). MSGS changes its symbol to MSGK
• Distribution ratio: one MSGR share for every two MSGS shares, applied identically to Class A and Class B; cash in lieu of fractions
• Tax treatment: intended tax-free pro-rata distribution of 100% of the SpinCo
• Conditions: final MSG Sports board approval, league approval, a tax opinion, and Form 10 effectiveness
• Entity: MSGS Spinco, Inc., incorporated in Nevada on April 28, 2026

Financial Structure (from the August 14 Form 10)

Three things stand out. First, the business does not currently make money: adjusted operating income swung from +$37.1M in FY2024 to -$14.2M in FY2025 and -$16.3M pro forma in FY2026. Second, it carries almost no debt — $16.5M, against $565M of pro-forma total assets. There is no separation-debt story here at all, which is unusual and favorable. Third, revenue is going backwards: $401.5M in FY2024 to $341.5M pro forma in FY2026, with local media rights falling from $39.1M (12% of revenue) to $35.3M (10%).

That media-rights line is the disclosed risk. The Rangers’ 20-year local telecast agreement runs through MSG Networks, and the Form 10 explicitly warns that conditions at MSG Networks — “including the work-out of MSG Networks… and/or actions by the NHL” — have already reduced this revenue and a bankruptcy of MSG Networks could reduce it materially further.

Share count: the pro formas are based on 24.2 million weighted-average MSG Sports Class A and Class B shares; at one MSGR per two MSGS shares, MSGR will have roughly 12.1 million shares outstanding. At $384.73 the combined entity carries a market capitalization of ≈$9.3B.

Management & Governance

This is the central governance fact and the reason the grade stops at B. James Dolan will serve as Executive Chairman and CEO of both successor companies, and of MSG Entertainment and Sphere Entertainment, and as non-executive Chairman of AMC Global Media. The Form 10 carries an explicit “Overlapping Directors and Officers and Potential Conflicts of Interest” disclosure covering five related entities. The Class B shares — which are not being listed — carry the control.

Investment Analysis

SpinCo (MSGR) Opportunity

• Strengths: Original Six NHL franchise in the largest US media market; scarce asset class (32 NHL franchises); essentially debt-free; franchise values have historically compounded well above the operating economics; a clean 100% distribution with no retained stake
• Risks: Loss-making at the operating line and revenue declining; MSG Networks credit risk directly threatens 10% of revenue; ≈12.1M shares means a very thin float; dual-class control means no path to a change of control; NHL approval is still outstanding
• Catalysts: Form 10 effectiveness and the record-date announcement (expected September/October); any resolution of the MSG Networks situation; national NHL media-rights economics

RemainCo (MSGK) Opportunity

• Strengths: The Knicks are the more valuable franchise and are coming off a championship season; a pure-play on the higher-growth league
• Risks: Same Dolan governance; same arena-license dependency on MSG Entertainment

Recommendation: The historical pattern for Dolan separations is that value accrues to whoever holds through the fragmentation, but the fragmentation itself is not the value event. Own MSGS into the record date to receive both — there is no cost to participating — but treat MSGR as an asset-value holding rather than an earnings story.

Investment Scorecard

Grade Change: Upgraded C+ (est. 2.20) → B (2.60). Trigger: the August 14 public Form 10, which converted this from a name with a confidential filing and no timetable into a transaction with a ticker (MSGR), a ratio (1-for-2), a target (end of October) and audited standalone financials. Per the methodology, dimensions previously scored 2 for missing data can be re-scored once the data arrives: Competitive Position moves to 4 on the disclosed franchise position, and Financial Profile stays at 2 — the filing shows the losses are real, not a data gap.

Acquisition Analysis (SpinCo)

Potential Acquirers: None realistically. An NHL franchise transfer requires league approval, and the Dolan family’s Class B position forecloses a hostile or negotiated change of control. The theoretical buyer universe — sovereign wealth, sports-focused private equity now permitted limited NHL stakes — can acquire minority economics at best. Acquisition Likelihood: Very Low. Impact on Thesis: None. The value case is franchise appreciation and any eventual media-rights reset, not a takeout.

Sources

• SEC — MSGS Spinco, Inc. Form 10 information statement (August 14, 2026)
• MSG Sports — Publicly files Form 10 registration statement for the proposed spin-off of the Rangers business
• StockSpinoffs — MSG Rangers spinoff (August 17, 2026)

Part 2B: BRIEF UPDATES — OTHER TRACKED UPCOMING SPINOFFS

• Keurig Dr Pepper → Global Coffee Co: Q2 (August 6) beat on EPS ($0.57 vs $0.54) on revenue of $7.309B and reaffirmed full-year guidance; US Refreshment Beverages delivered double-digit growth. Separation into Beverage Co. and Global Coffee Co. is still targeted for early 2027, with transformation workstreams aiming at operational readiness by year-end 2026. ⚠️ But the SpinCo still has no CEO. Rafael Oliveira departed at the end of July; the search Chairman Pamela Patsley opened in June is now in its third month; Tim Cofer continues to oversee coffee and will be Beverage Co CEO, and Patsley will chair Global Coffee Co. (B (2.95) maintained. The Management dimension cannot move above 2 until a permanent CEO is named, and this name will not be deep-dived again until one is.)
• Eaton → Mobility Group + Dana (RMT): No new August development, but the July valuation detail is now confirmed from both sides: the ≈$5.1B transaction represents ≈8.3x estimated 2026 pro-forma adjusted EBITDA before synergies, or ≈5.9x including run-rate synergies, with $250M of annual run-rate synergies targeted within 24 months and a ≈$1.1B cash distribution to Eaton (subject to cash/debt adjustment). Eaton will separate Mobility by exchange offer (split-off) or pro-rata distribution at its election — that election matters to holders and has not been made. Close Q1 2027. (B maintained.)
• Unilever → Foods/McCormick RMT: ⚠️ The CMA’s invitation to comment closed August 5, but as of the pricing date the regulator has not formally commenced a Phase 1 investigation — the process is still at initial information-gathering. Separately, Unilever is carving out Colman’s ahead of the deal, which reads as pre-emptive remedy management. Deal value ≈$45B ($15.7B cash + $29.1B stock); Unilever holders end with ≈65%, McCormick holders ≈35%. Mid-2027. (B maintained; UK antitrust remains the principal risk and the clock has not formally started.)
• McKesson → Medical-Surgical Solutions: No material August development. H2 2027 via the Apollo-investment route (≈13% minority stake, ≈$1.25B) rather than a clean spin. MCK +3.4% in August. (B maintained.)
• J&J → DePuy Synthes: ⚠️ The decision is now roughly three months past its guided window. The original October 2025 announcement guided 18–24 months to completion with a mid-2026 decision on spin-versus-sale; neither has arrived, and external trackers now frame the timing as “18–24 months from October 2025,” i.e. drifting into H2 2027. The asset itself is unchanged — ≈$9.2B of revenue, ≈10% of J&J, to be led by Namal Nawana — and a reported $20B+ private-equity sale remains the alternative path. (B maintained, decision flagged overdue for a second consecutive report. Under this report’s methodology a delay of this length is a red flag; it is offset here only by the quality and divisibility of the underlying asset.)
• Genuine Parts → Global Industrial (Motion): No material August development. Q1 2027; ≈$9B sales, $1.1B+ EBITDA. GPC +9.1% in August. (B maintained.)
• International Paper → EMEA Packaging: No material August development. Q1 2027; dual LSE + NYSE listing; IP retains 20% for 12–18 months; ≈$200M of EMEA cost reduction underway. (B maintained.)
• Flex → Power & Cloud Infrastructure: Leadership was named July 29 and is now complete: Revathi Advaithi as SpinCo CEO with Bill Watkins as non-executive chairman, Kevin Krumm CFO, Rob Campbell CCO, Hooi Tan COO, Mattias Jansson (Embedded Power) and Todd Hoover (Critical Power) as segment presidents; Michael Hartung becomes CEO of RemainCo Flex. ⚠️ The SpinCo name promised for September has still not been unveiled. Separately, FLEX shares are -32.6% since June 30 ($162.07 → $109.25) on the broad semiconductor and AI-hardware de-rating rather than company news. (B maintained; a name, a Form 10 and standalone financials remain the upgrade triggers.)
• HF Sinclair → Lubricants & Specialties: Real execution in August. On August 3 the business signed long-term commercial agreements with SK Enmove (distributing YUBASE Group III base oils in key North American markets) and Chevron Products (distributing Chevron-branded Group II base oils in Canada and select US regions) — the supply arrangements needed to replace the Mississauga base-oil capacity being retired. The segment also closed its acquisition of Industrial Oils Unlimited. The segment reported $207M of adjusted EBITDA in Q2 2026 as disclosed by the company, though the standalone SpinCo perimeter has not been defined, so that figure should not be read as the SpinCo’s earnings power. DINO +11.1% in August. (B maintained — no SpinCo leadership named, no Form 10, no date beyond “12–18 months.”)
• Medtronic → MiniMed full exit: ⚠️ Timing loosened. Q1 FY27 (quarter ended July 31; reported in August) delivered revenue of $9.8B, +13.7% organic, with diabetes revenue +15%, and management reaffirmed the separation — but framed it as completing “before fiscal year-end” (April 2027) and “when the economics are optimal for stakeholders,” rather than the year-end 2026 previously guided. Medtronic still owns ≈90%; the stated preferred structure remains a split-off (an exchange of MDT shares for MMED shares). MMED $20.26, above its $20 IPO price for the first time. (B- maintained; the softer language is a mild negative offset by a strong parent quarter.)
• L3Harris → Missile Solutions (MSL): No August development following the July 29 postponement to mid-2027. The confidential Form S-1 (submitted April 29) stands; the $1B Department of War convertible preferred still converts at IPO, with LHX retaining ≈80%+. LHX -3.9% in August. (B- maintained.)
• Textron → Industrial: No August development. Path still undecided between an outright sale and a tax-free spin; Industrial (Kautex + Textron Specialized Vehicles) quantified at >$3B revenue; trackers place completion in Q2–Q3 2027. TXT -5.5% in August. (B- maintained.)
• Adaptive Biotechnologies → Immune Medicine: No change to the plan; preferred separation path still due by year-end 2026, Morgan Stanley retained, FY 2026 MRD revenue guidance $268–278M. ADPT +10.4% in August. (B- maintained; the structure decision is the catalyst and it is now four months away.)
• Solventum → Health Information Systems (NEW): Announced August 5 alongside a Q2 beat. Solventum will pursue a separation of Health Information Systems — ≈16.3% of the company’s ≈$8.3B of net sales, so ≈$1.36B of revenue — leaving a pure-play MedSurg and Dental medtech. Morgan Stanley and Goldman Sachs are advising, Cleary Gottlieb is counsel, and the timeline is 12–18 months. ⚠️ The announcement is deliberately non-committal on structure: the company will “evaluate a range of separation pathways with the objective of maximizing shareholder value.” This is Solventum’s second separation in under two years, having itself been spun from 3M in April 2024. Initial grade B- — a credible portfolio action with real advisors, but no structure, no leadership, no financials and no date. Under the methodology, undisclosed dimensions score 2 and the grade is provisional pending a structure decision.
• Spectrum Brands → Home & Personal Care: No August development. Confidential Form 10 on file since 2024; spin, sale or merger all still live; no timetable. (C+ maintained.)
• New Fortress Energy → BrazilCo / CoreCo: ⚠️ The Q3 2026 target has effectively lapsed. The English court sanctioned the Part 26A plans on June 18 and the SDNY granted Chapter 15 recognition on July 14, but no completion of the BrazilCo/CoreCo separation has been announced and the quarter ends in four weeks. NFE trades at $0.29, -9.4% in August and -19.4% since June 30. (C maintained — a creditor-led restructuring in which existing equity is heavily diluted, now also behind schedule.)
• ABVC BioPharma → BioKey: ⚠️ The ≈August 3 distribution date passed with no completion announcement located. Carried as a footnote with status unconfirmed. Footnote only.
• Jet.AI → Data Center Co. (DCTR), Click Holdings → Logistics, Vivani Medical → Cortigent (NEW): Micro-cap announcements with no terms, no financials and, in Jet.AI’s case, only a non-binding letter of intent. Footnotes only — none is investable on current disclosure.
• UPM-Kymmene → WISA Group (NEW, non-US): A Helsinki-listed plywood and wood-products separation dated October 31, 2026 by external trackers. Monitored for any US-listing path; not individually tracked, consistent with this report’s treatment of non-US separations.

Part 3: COMPLETED SPINOFFS — Extended Post-Spinoff Analysis

All prices as of August 31, 2026 close (verified daily data). SpinCo returns vs the Day-1 reference basis fixed in prior reports (open or close as noted per name); post-spin low = lowest closing price since the first regular-way trading day.

COMPLETED SPINOFFS SUMMARY TABLES

Table A: Overview & Ratings

Sort: by spinoff date, most recent first. All SpinCo returns vs Day-1 reference unless noted. Parent baselines are each parent’s first regular-way (ex-distribution) close, on the convention adopted last report. Ralliant (RAL) and Sandisk (SNDK) are added to Part 3 this edition — both separated inside the window this table already covers (June 2025 and February 2025) and both now carry a first investment grade; see §20 and §21. † Honeywell’s pre-breakup comparison remains not meaningful (3-way breakup + 1-for-2 reverse split on Jun 29); HON is tracked from its Jun 29 post-spin close in Table D. ‡ DuPont (DD) is shown split-adjusted for its 1-for-3 reverse split (Jun 24); raw quoted price $134.59.

Table B: SpinCo Price Performance & Post-Spin Low Recovery (Updated August 31, 2026)

Sort: by spinoff date, most recent first. Post-Spin Low = lowest closing price since the first regular-way trading day (daily OHLC). New lows set in August: HONA ($156.47, Aug 6, day 38 — a -23.1% single session), FDXF ($128.75, Aug 25, day 85 — its second consecutive monthly new low), MBGL ($19.00, Aug 10, day 40 — undercutting its July 6 trough), plus a first trough for ADIG ($20.50, day 14). Neither new name set a low this month — RAL troughed at $38.39 on Feb 5, 2026 (day 220) and SNDK at $29.62 on Apr 22, 2025 (day 57). NVRI Day-1 basis = Jun 2 regular-way close (holders separately received $15.00/sh cash). SNDK’s +3,123.7% is a NAND pricing cycle, not a spinoff outcome — see §21 before reading it as one.

Table C: SpinCo Performance Since Last Report (Jul 31 → Aug 31, 2026)

Sort: by % change since last report, best first. A far calmer month than July at the index level but with one violent idiosyncratic break: HONA (-23.5%) on a guidance cut, against a broad recovery in the beaten-down cohort — RNA, VSNT, MMED and OCTV, the four names this report has carried at its lowest ratings, took four of the top seven slots. Eleven of twenty-one comparable names rose, versus six of seventeen last month. ADIG has no prior-report comparison. SNDK’s +29.0% follows a -46.6% July, which is the character of the name rather than an anomaly.

Table D: Parent Company Performance Post-Spinoff

Sort: by spinoff date, most recent first. * UL share-consolidation adjusted. † The pre-breakup Honeywell line is retained for continuity only. ‡ DD shown split-adjusted (1-for-3 reverse split Jun 24); raw quoted price $134.59. Note on REZI: market-data providers applied the ADI distribution to Resideo’s history as a 1.437 adjustment factor on August 4, so REZI quotes shown for dates before August 4 in adjusted price series are scaled down by that factor and are not the prices at which REZI actually traded. This table uses the first regular-way ex-distribution close of $26.17 on August 4 as the baseline, the same convention applied to MBGL, MFP and HONA.

Post-Spin Low Recovery — Pattern Analysis (updated)

• August separated two kinds of post-spin low, and the distinction is the most useful thing in this edition. HONA troughed on day 38 — squarely inside the forced-selling window this report has flagged for a year — but it got there via a -23.1% single session on a guidance cut, not through index-fund selling. Every previous day-20-to-day-60 trough in this dataset (SOLS day 19, Q day 21, VSNT day 38, TRAX day 44, OCTV day 56) was a liquidity low that resolved upward on no new information. HONA’s is an information low: 2026 earning power is genuinely ≈8% lower than it was on August 5. The two must be underwritten differently — a liquidity low is bought on the calendar, an information low only on the arithmetic that follows it. Here the arithmetic supports it anyway: at 17.9x forward against peers at 25–50x, with a flat-margin-forever bear case of ≈$163 and the stock at $158.11, the information low overshot the information. But that is a conclusion reached by re-underwriting the business, not by the pattern.
• The mechanical lows continue to work. MBGL undercut its July trough with a new low of $19.00 on day 40 and closed the month at $20.30, +6.8% off it, on a quarter that beat and a maiden dividend — a textbook liquidity low. ADIG troughed at $20.50 on day 14 and is +6.7% off it. OCTV, which bottomed on day 56 in July, is now -1.7% vs Day 1 from -10.4% and has confirmed the higher low this report was waiting for. That is the pattern completing in real time.
• The retained-stake discount is now the most reliable finding in this dataset. FDXF set its second consecutive monthly new low, on day 85 ($128.75), and sits -10.6% vs Day 1 — worse than a month ago — while every 100%-distributed spin from the same window has recovered off its trough. MMED (≈90% parent stake) took 178 days to regain its IPO price. CHRN (≈97% parent stake) fell -17.5% on nothing but float mechanics. Three structures, three overhangs, three underperformances. This is the direct evidence behind the discount applied to Comcast/NBCUniversal (up to 19.9%), International Paper EMEA (20%) and, most severely, Barrick’s North American IPO (85–90%).
• The worst-rated cohort outperformed, and one of them changed character. RNA (+17.4%), VSNT (+14.3%), MMED (+12.2%) and OCTV (+9.6%) — four of the top seven — are the four names this report has carried longest at SPECULATIVE or HOLD. RNA is the notable one. This report has argued for five months that pre-acquisition carve-outs are the weakest structure in the taxonomy because they are assets the acquirer did not want, spun to holders with no natural buyer base. August produced the first genuine counter-evidence: an FDA IND clearance, a Phase 1/2 trial launch and a $15M partner milestone. The structural argument still holds — RNA remains -9.7% vs Day 1 after six months — but the thesis now has a live test rather than a foregone conclusion.
• Parents had a worse month than SpinCos, for the second month running. REZI -26.0% from its ex-distribution close, MIDD -20.4%, APTV -42.4% over the cycle, APLD -36.3%, LEN -29.8%. The recurring mechanism is visible in Resideo: the RemainCo beat its quarter, then reset guidance to a smaller standalone perimeter, and the market marked it down 19.3% in a session. A parent’s first standalone guide is a repricing event, not an earnings event — and it lands three to eight weeks after the spin, which is exactly when the SpinCo’s own forced-selling window is closing.

Per-name sections below are ordered by spinoff date, most recent first — the same rule as Tables A, B and D.

1. ADI GLOBAL DISTRIBUTION (ADIG) ⭐⭐⭐ B — HOLD (NEW — completed Aug 3-4)

• Current Price: $21.87 (Day-1 close $22.00 → -0.6%); post-spin low $20.50 on August 18 (day 14), now +6.7% off it.
• The deal: Record date July 20, distribution August 3, first regular-way NYSE trading August 4. One ADIG share per two REZI shares, cash in lieu of fractions, 100% distributed. ≈75.9M shares. ADI entered independence with $4.8B of 2025 revenue, ≈4,100 employees and nearly 200 store locations as a global specialty distributor of professionally installed low-voltage products. CEO Robert Aarnes.
• The round trip: this was the most instructive price action of the month. ADIG opened its regular-way life at $22.00, ran +28.5% to $28.27 by August 10 as index and event-driven buyers established positions, then gave back every cent of it in the four sessions following the August 12 earnings release, bottoming at $20.50. Buying the debut and buying the pop both lost money; only the day-14 trough worked.
• First standalone quarter (August 12): record revenue of $1.29B (+1%, average daily sales +2% against one fewer selling day), segment adjusted EBITDA of $103M, and net income of $6M against a $283M net loss in the prior-year quarter. Both revenue and segment EBITDA beat the high end of guidance.
• ⚠️ But the guidance is the problem. Management reiterated full-year 2026 revenue of $4.95–5.00B and adjusted EBITDA of $275–295M — a 5.6–5.9% margin against the 6.6% ADI earned in FY2025, on higher revenue. A distributor guiding margin compression in its first standalone year is exactly the profile the July downgrade was written about, and the quarter did not change it.
• Valuation: at $21.87 on ≈75.9M shares the market capitalization is ≈$1.66B; adding the ≈$1.0B of separation debt gives an enterprise value of ≈$2.7–2.8B, or 9.0–10.2x the FY26 adjusted EBITDA guidance. That is not a distressed multiple for a business earning under 6% margins with CD&R holding ≈19.69% of voting power and two board seats.
• Grade B (2.80) maintained; HOLD. The beat is real and the exclusive-brands mix shift (4% → 18% of revenue since 2023) is the variable that could re-rate this. But nothing in the first quarter contradicts the Form 10 read, and the upgrade trigger remains unchanged: the mix shift converting into reported EBITDA expansion, which the FY guidance says will not happen in 2026.
• Parent REZI $19.36 (-26.0% since the August 4 ex-distribution close) — see the note on Resideo under Table D.
• ADI Global Distribution completes spin-off from Resideo and begins NYSE trading
• ADI announces second quarter 2026 financial results

2. MIDERA FOOD PROCESSING (MFP) ⭐⭐⭐ B+ — HOLD

• Current Price: $46.88 (-2.2% in August; +28.1% vs the $36.60 Day-1 close). The post-spin low remains the first close; MFP has never traded below its debut.
• First standalone quarter (August 13, fiscal Q2 ended July 4): net sales $245M, +13.2% (+1.2% organic), estimated standalone adjusted EBITDA of $42M — a 17.1% margin — above the high end of the $37–41M guidance range. Net earnings $11M vs $29M a year ago (separation costs). Orders +16%, backlog $446M. Full-year guidance was raised: at the midpoint, net sales +11%, organic +6% and standalone adjusted EBITDA +20%.
• Assessment: a beat and a raise, and the stock went nowhere. That is a better setup than July’s, when a +31% three-week re-rating had closed the entry window on unchanged fundamentals. But the valuation still does not demand action: at $46.88 on ≈45.2M shares the market capitalization is ≈$2.1B, and with ≈$0.3B of net debt an enterprise value of ≈$2.4B — roughly 14x the Q2 EBITDA run-rate annualised. Grade B+ maintained; HOLD — a good business at a fair price, with the 20% EBITDA growth guide the thing to hold it for.
• Parent MIDD $110.84 (-20.4% since the spin) — the pure-play foodservice RemainCo also beat (adjusted EPS $2.35, revenue $875.6M, organic +8.3%) and also fell, on tariff costs and a softer second-half outlook. Both halves of this separation have now beaten and been marked down, which says more about the multiple the market will pay for foodservice equipment than about either business.
• Midera Food Processing reports Q2 2026 results in its first report as an independent public company

3. MOBILITY GLOBAL (MBGL) ⭐⭐⭐⭐ A — BUY

• Current Price: $20.30 (-0.4% in August; -4.2% vs the $21.19 Day-1 close). Set a new post-spin low of $19.00 on August 10 (day 40), undercutting the July 6 trough, and recovered +6.8% off it.
• The first standalone quarter (August 7) validated July’s corrected figures. Every number this report re-based in July held:

• FY2026 guidance: revenue $1,870–1,885M (+6.9–7.7%), adjusted EBITDA $745–760M, ≈40% margin.
• 💰 The dividend is real, and roughly double this report’s July estimate. The board declared a first quarterly dividend of $0.06 per share, payable September 10 — $0.24 annualised, a 1.18% yield at $20.30. July’s model, working from a stated policy of 20–25% of GAAP net income, projected $0.115–$0.187 per share. Management is paying out more than its own framework implied, which is a modestly more shareholder-friendly stance than assumed.
• ⚠️ One timing item runs the other way. July’s model projected ≈$496–507M of 2026 free cash flow. 1H26 free cash flow was $177M, down ≈20% year over year, on $57M of separation costs and working-capital timing. This is a 2026 timing effect, not a reset of the earning power — the stand-up drag is front-loaded and framed as a 12–18 month item, and the FY2025 figure of $461M, 26.3% of revenue, remains the right basis for valuing the business. What should be adjusted is the calendar: the 2026 total-distribution and capital-allocation scenario tables in July’s Part 3 §2 are better read as a 2027 case.
• The full-year guidance discloses a second-half step-down, and it is not a stumble. A guided FY26 adjusted EBITDA margin of ≈40.1% against 41.8% delivered in the first half implies a second half at 38.4% — almost entirely the standalone cost load arriving on schedule.
• Four years of segment history support the story rather than undercutting it. S&P Global reported Mobility as a segment from 2022, and the figures reconcile to Mobility Global’s own within $3M: revenue $1,142M → $1,484M → $1,609M → $1,747M, with segment operating profit up 77% against revenue up 53%. A pre-separation growth claim surviving the longer record is not the usual outcome in this report.
• Balance sheet, in full: the ≈$1,900M paid to S&P Global was funded by three fixed-rate tranches — $650M at 5.050% due 2029, $650M at 5.450% due 2031 and $700M at 6.050% due 2036 — a 5.53% weighted coupon, ≈$111M of annual cash interest, no floating-rate exposure and nothing due before 2029. Net debt ≈$1,795M is 2.39x guided FY26 EBITDA (2.63x gross), and the $500M revolver is undrawn. There is no refinancing wall to underwrite.
• Valuation at $20.30: ≈295.1M shares → $5.99B market cap; net debt ≈$1.80B → EV ≈$7.79B. That is 10.2–10.5x FY26 guided EV/adjusted EBITDA and 13.0x FY2025 free cash flow, a 7.7% free-cash-flow yield.
• Free cash flow is the only honest measure here, and the reason is specific. Mobility Global carries $8,845M of goodwill and $3,640M of intangibles from S&P Global’s IHS Markit acquisition. Amortization of acquired intangibles is $296M a year — 16% of revenue — against capital expenditure of roughly $25M (1.3% of revenue). That pushes GAAP earnings far below cash earnings. Running the other way, cash taxes run $80–90M above the GAAP provision, and adjusted EBITDA ignores that entirely. So EBITDA overstates and GAAP earnings understate: reported operating margin runs ≈18% against a ≈40% adjusted EBITDA margin, and neither is the economics. Free cash flow absorbs both.
• The capital-returns arithmetic is the most interesting decision in front of management. At $20.30 the shares yield 7.7% on free cash flow while retiring debt saves ≈4.1% after tax — buying stock is worth roughly 350 basis points more than repaying borrowings, on a business with 82% subscription revenue and no maturity until 2029. Sustained repurchases at this valuation would retire roughly a quarter of the company over five years. But buybacks are guided to begin in 2027, not now — and a team that defers repurchases at 13x free cash flow to reach a leverage target the maturity schedule does not require would be optimising the balance sheet at the owners’ expense. The 2027 start date is a commitment worth holding them to.
• Grade A (4.35) maintained; ⭐⭐⭐⭐ BUY. Target $28. The quarter confirmed the margin, the guidance brackets it, and the dividend exceeded the estimate. The question was never the multiple — it is whether CARFAX’s 8% growth is durable, and nothing in the first standalone quarter argues against it.
• Parent SPGI $435.84 (+5.0% since the spin) — the clean, zero-retained-stake structure continues to leave no overhang on either side, and both halves are now positive from their respective baselines.
• Mobility Global reports second quarter 2026 financial results
• SEC — Mobility Global Form 8-K, Q2 2026 results

4. HONEYWELL AEROSPACE (HONA) ⭐⭐⭐ B+ — BUY ⬇️ (grade cut two notches from A; rating raised to BUY)

• Current Price: $158.11 (-23.5% in August; -28.2% vs the $220.19 Day-1 close). Post-spin low $156.47 on August 6 (day 38), reached in a -23.1% single session; the stock has recovered just +1.0% off it in the seventeen sessions since.
• What happened on August 6: Q2 missed and the standalone guidance was cut, six weeks after the company started trading. Organic sales growth went to 4–5% from 7–9%, pro-forma standalone adjusted EBITDA to $4.35–4.45B from $4.65–4.75B, and 2026 adjusted EPS to $7.60–7.90 against an $8.86 consensus. Q2 sales were $4.5B (+5%) with adjusted EBIT of $995M (-7%) and adjusted EPS of $1.87 against $2.75 a year earlier.

⚠️ Correction: the casting shortage is not the story

This report’s first read attributed the deterioration to the precision-casting supply crunch management cited on the call. Working through six years of Honeywell’s segment disclosure — the FY2022 and FY2025 Forms 10-K, alongside HONA’s own Q2 10-Q filed August 5 — shows that explanation does not survive the record.

Four consecutive periods of decline, 405 basis points, and most of it landed before precision castings were ever mentioned. The casting constraint is real and it is compressing the current quarter, but it is the most recent layer on a trend that started two years earlier.

The actual cause is mix, and it was a deliberate choice. Defense and Space went from 36.6% of segment sales in 2023 to 41.2% in 2025, growing 18–22% a year while the higher-margin commercial aftermarket grew 9–15%. Honeywell paid $1.9B for CAES ten months before separating the segment — it reshaped the business toward defense on the way out the door.

Read that as strategy rather than decay. HONA holds an estimated 65–80% of the commercial APU market with sole-source positions on a 25-year installed base. That is a ceiling, not an engine. Defense is a far larger market where it is a participant with share to win, and absolute segment profit grew $1.2B, or 40%, between 2021 and 2025 while the margin rate fell. Trading rate for a bigger opportunity set is the right move from a dominant position in a mature niche. The risk is not that the earnings are worse — it is that the market pays ≈20x for defense-weighted aerospace and 32–38x for aftermarket-weighted aerospace, so the multiple can fall further than the earnings rise.

⚠️ Correction: the balance sheet is not the problem either

This report described “≈$15.8B of long-term debt and negative book equity.” Both figures are directionally right and the framing was wrong. Net debt is $14.8B — 22% of enterprise value, at a 4.96% weighted coupon, with 5.5x interest coverage and nothing maturing before 2028. That is unremarkable. The negative book equity is an accounting artifact of distributing $15.1B to the parent, not a statement about economic net worth. What the leverage costs here is optionality, not solvency.

The genuine cash-flow concern is narrower and more specific: first-half free cash flow was $86M, flattered by $344M of receivables sold. That leaves little cushion before the November print, and rising factoring borrows reported cash from future periods.

Valuation — and why the rating goes up while the grade goes down

At $158.11 on ≈317.0M shares the market capitalization is ≈$50.1B and enterprise value ≈$66.6B. That is 17.9x forward earnings against an aerospace peer group at 25–50x — the cheapest name in the sector. A discounted cash flow at a 26% terminal margin and a 9.0% discount rate, explicit to 2040, returns ≈$205. The bear case — margin flat at 23.5% forever, discounted at 9.5% — is ≈$163, and the shares closed the month at $158.11, below even that. Backlog is up 9% and orders up 8%.

Rating raised to ⭐⭐⭐⭐ BUY. Target $195. You are being asked to pay for none of the recovery.

• Grade Change: Downgraded A (4.05) → B+ (3.20) — a two-notch cut. The trigger is evidence that was always available in Honeywell’s segment filings and had not previously been examined, not the August guidance cut. The prior A was set before separation, on a Form 10 and a $37B backlog figure that belonged to the parent; it was never tested against six years of segment data or a standalone balance sheet. Every other revision in this cycle moved a score without moving a band; this one moves two, and it should.
• Recommendation: ⭐⭐⭐⭐ BUY. Target $195. The grade and the rating point opposite ways here, and that is deliberate. The grade says this is a weaker business than the pre-spin A assumed — more defense-weighted, more levered, with a margin trend that was never tested against the long record. The rating says the price already reflects more than that. A B+ business at a C+ price is a buy, and the bear case being today’s quote is what makes it one. This supersedes the HOLD carried earlier in this cycle, which rested on the casting-shortage reading.
• What would earn the grade back: two quarters of margin stabilisation, 2H free cash flow at the top of the guided range, and evidence that the aftermarket is reaccelerating past defense. What would make it worse: a second guidance cut, 2H free cash flow below $1.0B, rising receivables factoring, defense growing past 45% of sales, or aggressive buyback execution above $190.
• Next catalyst: the Q3 print in November, which settles both the cash-conversion question and whether the casting constraint is easing.
• Parent Honeywell Technologies (HON) $213.53, -6.3% since the June 29 baseline — HON fell in sympathy despite no longer owning the business, giving back all of July’s outperformance.
• SEC — Honeywell Aerospace Form 10-Q, quarter ended June 27, 2026 (filed August 5)
• Honeywell Aerospace reports second quarter results and updates 2026 guidance
• SEC — Honeywell International Form 10-K, FY2025 (Aerospace segment record)
• SEC — Honeywell International Form 10-K, FY2022 (Aerospace segment record)

5. FEDEX FREIGHT (FDXF) ⭐⭐⭐ B+ — HOLD ⬇️ (downgraded from A- / BUY)

• Current Price: $133.74 (-4.8% in August; -10.6% vs the $149.53 Day-1 close). Set a second consecutive monthly new post-spin low, $128.75 on August 25 (day 85), and sits +3.9% off it.
• Two primary documents landed this month that post-date the last published grade: the FY2026 Form 10-K (filed August 5, for the year ended May 31, 2026) and the calendar-year 2025/2024 recast furnished August 6 after the fiscal-year-end change to December 31. Last month this report noted their existence as housekeeping. Read properly, they change the grade.

What nine years of segment disclosure show

The adjusted operating ratio was 88.3% in the year just ended, against 80.0% at the FY2023–24 peak — a cyclical trough, not a broken business. But the long record says the peak was the anomaly, not the trough. FedEx Freight ran 87.2% to 93.9% in the five years before FY2022, and reached 80% only during the post-COVID freight boom and the year Yellow liquidated. Mid-cycle is 85%, not 82.5% — and that single revision is worth roughly $15 a share.

Two negatives the pre-spin work could not see:

• Volumes are falling: average daily shipments -4%, and -24% from the FY2019 peak
• Reported earnings contain $373M of related-party interest income that ends at separation, replaced by ≈$206M of interest expense on the $4.3B of new debt raised to pay the parent

One thing better than previously assessed: CEO John Smith ran this exact business from 2018 to 2021 and improved its operating ratio 470 basis points doing it, and CFO Marshall Witt was a public-company CFO for twelve years and executed the Concentrix spinoff. The “no standalone track record” markdown was too harsh and is reversed below.

Valuation — and why the retained stake is worse than a discount

At $128.75 the shares traded at 16.3x trailing EBITDA against a peer median of 15.2x, while carrying 3.8x leverage including leases — the most in the LTL group. At $133.74 that premium is wider. There is no spinoff discount here to buy.

And the overhang is now dated rather than open-ended: FedEx must sell its retained 19.9% before June 2028 — a known, forced seller of roughly 29 days’ trading volume. FedEx’s chairman also chairs this board, which aligns the placement incentives but underlines the point: this is a 19.9%-owned affiliate, not yet a fully independent company.

• Grade Change: Downgraded A- (3.80) → B+ (3.15). The trigger is the arrival of the FY2026 10-K and the calendar-year recast, which supplied nine years of operating-ratio history the pre-spin grade never had. This is a data-availability correction, not a business deterioration — the operator is the same one; the mid-cycle assumption it was graded against was too generous. Note that Management & Governance moved up within a two-notch downgrade: the same documents that cut the financial score corrected an unfair markdown on the team.
• Recommendation: ⭐⭐⭐ HOLD. Target $108. This report has carried a BUY on FDXF since the spin on the argument that the A- priced the overhang and the entry would come. Three months of trading did produce the drawdown — and the long record now says the business is worth less than the drawdown implies. At 16.3x trailing EBITDA against a 15.2x peer median with the group’s highest leverage, the discount was never there. Revisit if the operating ratio breaks below 85% for two consecutive quarters or if FedEx places its stake at a clearing price.
• Parent FDX $327.40 (-3.3% since the spin, +6.5% in August) — the parent has materially outperformed the SpinCo, the reverse of the pattern in cleanly distributed separations.
• SEC — FedEx Freight Holding Company Form 10-K, FY2026 (filed August 5, 2026)
• SEC — FedEx Freight calendar-year 2025/2024 recast (furnished August 6, 2026)

6. NEW ENVIRI (NVRI) ⭐⭐⭐ B — HOLD

• Current Price: $22.28 (+0.5% in August); +16.0% vs the June 2 regular-way close ($19.20), plus the $15.00/share cash holders received separately. +25.5% off its day-1 low.
• A third consecutive quiet month. The spin + paired-sale structure (Clean Earth → Veolia for $3.04B; Harsco Environmental + Rail spun as New Enviri) left a deleveraged industrial-services and rail pure-play that has done exactly what a deleveraged industrial-services pure-play does: gone sideways at a modest premium to its debut. The taxable structure and cyclical end-markets keep it at B — HOLD; the cash component materially de-risked the outcome and remains the reason this ranks above the other B-graded completions.

7. OCTAVE INTELLIGENCE (OCTV) ⭐⭐⭐⭐ — BUY ⬆️ (upgraded from HOLD)

• Current Price: $20.00 (+9.6% in August); -1.7% vs the ≈$20.35 Day-1 open, and +29.0% off its July 23 post-spin low ($15.50, day 56).
• The pattern completed. In July this report wrote: “HOLD moving toward BUY — a confirmed higher low would complete the pattern.” August delivered it. OCTV did not revisit the $15.50 trough, spent the month grinding higher and closed within 2% of its first-day open. An eight-week forced-selling window, a 24% drawdown and a full round trip is the textbook life-cycle this report’s framework describes, and it has now run start to finish.
• The asset was never the question. A high-quality asset-lifecycle software business (≈EUR 1.45B revenue, ≈31% adjusted operating margin) dual-listed on Nasdaq New York and Nasdaq Stockholm, with sell-side targets well above the current quote. Upgraded ⭐⭐⭐ HOLD → ⭐⭐⭐⭐ BUY.
• Parent Hexagon (HXGBF) $10.53, +17.0% since the spin — both halves now positive, another clean-distribution outcome.

8. CHRONOSCALE (CHRN) ⚠️ — SPECULATIVE

• Current Price: $18.18 (-17.5% in August); still +37.5% vs its May 5 debut close ($13.22), which remains its post-spin low.
• No company news drove the decline. The RMT structure — Applied Digital contributed its cloud business to EKSO Bionics, renamed ChronoScale, with APLD retaining ≈97% — leaves a float so thin that price action is dominated by supply and by sentiment toward the parent. Parent APLD $25.41 (-36.3% since the spin, -7.2% in August). Over four months the parent has lost more than a third of its value while the SpinCo has gained more than a third, and both moves are float mechanics rather than business outcomes. SPECULATIVE — the thinnest float in the tracked set and not a position to size.

9. FIRST TRACKS BIOTHERAPEUTICS (TRAX) ⚠️ — SPECULATIVE

• Current Price: $41.84 (-5.0% in August, after July’s +118.9%); +124.9% vs the $18.60 Day-1 close and +173.1% off its June 3 low.
• Q2 (August 12): the company reiterated a broad development strategy for ANB033, its CD122 antagonist, and expects to be treating patients across four indications in 2027. On August 26 it announced participation in the Wells Fargo Healthcare and Citi Biopharma conferences in September.
• Assessment: July’s judgment holds without amendment. This is a pre-revenue, cash-burning clinical-stage biotech that more than doubled on a competitor’s Phase 1b data and Russell index inclusion, and it gave back 5% in a month with no news. The analyst targets that looked aspirational at $16 (UBS $45, Leerink $46, Barclays $40) now sit around or below the market. SPECULATIVE — a position to trim into strength ahead of ANB033’s own readouts, not to add to.

10. VERSIGENT (VGNT) ⭐⭐⭐⭐ B+ — BUY (first grade: B+ 3.20)

• Current Price: $47.40 (+14.6% in August); +70.2% vs the $27.85 Day-1 close, +75.9% off its day-6 low. A fresh all-time high.
• Q2 (August 4): net sales $2,444M, +10.8% (≈+5% adjusted); adjusted EBITDA $272M, +24.8%, an 11.1% margin (+120bps); net income $118M, +10.3%. Guidance raised and tightened, and a dividend declared.
• The cheapness is real; the growth story is thinner than two quarters make it look. At $47.40 Versigent trades at roughly 4.9x EV/EBITDA and ≈7.4x normalized earnings — below BorgWarner at ≈7.5x, below the 5.5–8.5x range for Tier-1 supplier transactions, and below the 8–12x P/E where auto suppliers usually trade. But the Form 10’s three years of carve-out history show revenue going $8,832M → $8,309M → $8,818M — a -0.1% CAGR, and adjusted operating margin cycling 7.6% → 6.9% → 7.6% before 7.9% in 1H26 and 9.0% in Q2. The last quarter is the best in the company’s recorded history; it is also one quarter, and Q1 2026 was down year on year.
• The comparison is still the point. VGNT +70.2% against parent APTV -42.4% is the widest SpinCo/RemainCo divergence in this dataset, and August widened it: Versigent hit a record while Aptiv cut 2026 guidance and hit a 52-week low.

• Grade Change: First grade for this company — B+ (3.20). Versigent has been carried as a completed spinoff without a letter grade since April. The Form 10’s three-year carve-out history and two quarters of standalone reporting are now enough to score it.
• Recommendation: ⭐⭐⭐⭐ BUY. Target $62 (base case ≈+31% from here). The bear case — flat revenue forever at the three-year average margin — is roughly fair value, not a loss. You are paying a distressed multiple for a business that has proven it can earn ≈7.5% margins through a cycle, with a free option on the Q2 improvement proving durable. What would take it to A-: two or three quarters establishing that the growth and the 9.0% margin are a trend rather than a recovery off a soft 2024.

11. JANUS LIVING (JAN) ⭐⭐⭐ — BUY

• Current Price: $29.75 (-1.5% in August); +26.1% vs Day 1 / +48.8% vs the $20 IPO; +30.0% off its day-7 low. A pause after July’s all-time high.
• Still the exception that proves the rule on carve-outs: a REIT structure and senior-housing demand have let JAN trade like a clean spin despite Healthpeak retaining majority control — the only retained-stake name in this report that has escaped the overhang discount. Parent DOC $20.82 (+4.1%). BUY.

12. MINIMED (MMED) ⚠️ — SPECULATIVE

• Current Price: $20.26 (+12.2% in August); +6.4% vs the $19.05 open and, for the first time, above the $20.00 IPO price (+1.3%) — 178 days after listing. +87.6% off its May low ($10.80, day 70).
• What is driving it: Medtronic’s Q1 FY27 (August) reported diabetes revenue +15% on US acceleration and international growth, following the earlier expansion of MiniMed Flex availability to Medicare and Medicare Advantage beneficiaries.
• ⚠️ The structure is the constraint, and its timing just loosened. Medtronic still owns ≈90%, and management now describes completing the separation “before fiscal year-end” — April 2027 — and “when the economics are optimal for stakeholders,” rather than the year-end 2026 previously guided. The stated preferred structure remains a split-off: an exchange of MDT shares for MMED shares, whose terms will determine both the real float and the tax treatment for exchanging holders.
• SPECULATIVE maintained. Taking 178 days to reclaim an IPO price while the underlying business grew 15% is the cost of a ≈90% overhang, stated as plainly as this dataset can state it. Parent MDT $90.65 (+6.2% in August, -3.0% since the IPO).

13. ATRIUM THERAPEUTICS (RNA) ⚠️ — SPECULATIVE (the month’s best mover among previously graded names)

• Current Price: $13.32 (+17.4% in August, second only to Sandisk, which is new to coverage); -9.7% vs the ≈$14.75 Day-1 open, up from -23.1% a month ago, and +19.1% off its July 29 low ($11.18, day 151).
• The first real fundamental news since the spin, all reported August 13:
  • FDA cleared the IND for ATR-1072, and the company launched Corventis — its first Phase 1/2 trial and the first clinical study of a potential disease-modifying treatment for PRKAG2 syndrome. Site activation is underway with first enrollment expected by end-2026
  • A second milestone under the global cardiovascular collaboration with Bristol Myers Squibb was achieved in August, triggering a $15M payment to be recognized in Q3
  • $263.9M of cash, cash equivalents and short-term investments at June 30 — a multi-year runway for a company of this size
• Assessment and a note on this report’s own thesis. For five months this report has argued that pre-acquisition carve-outs are the weakest structure in the taxonomy — assets an acquirer did not want, distributed to holders with no natural buyer base and long-dated catalysts — and RNA was the evidence. August is the first month that argument has been tested from the other side: a regulatory clearance, a trial launch and a partner milestone are exactly the catalysts the structural argument said would take years to arrive. The structural claim still stands on the numbers (RNA is -9.7% vs Day 1 after six months, the worst clean-spin return in the set), but it is now a live question rather than a settled one. SPECULATIVE maintained — a clinical-stage company with no revenue is not a rating this report will raise on an IND clearance.

14. VERSANT (VSNT) ⭐⭐⭐ — HOLD

• Current Price: $41.12 (+14.3% in August); -9.0% vs the $45.17 Day-1 open, improved from -20.3% a month ago, and +50.0% off its February low ($27.42, day 38).
• Q2 (August 6): the brands reached more than 120 million viewers a month, and the growth came from the platforms business — Fandango, Rotten Tomatoes, GolfNow, GolfPass, SportsEngine — plus the newly acquired Full Swing. The cable networks (MS NOW, CNBC, USA, Syfy, E!, Oxygen) remain in secular decline; the equity story is whether digital platforms can outgrow them.
• Why this matters beyond VSNT: this is the read-across for Comcast’s much larger NBCUniversal spin, and it improved materially. A market that priced Comcast’s first media carve-out down 39% from its open in February has repriced it to -9%. HOLD maintained — the recovery is real but linear decline is unresolved, and after a +50% move off the low this is no longer the discounted entry it was. The $27–28 zone is now far below the market and no longer a live trigger. Parent CMCSA $26.62 (-4.2%).

15. MAGNUM ICE CREAM (MICC) ⭐⭐⭐ — HOLD

• Current Price: $20.42 (+9.7% in August); +37.0% vs Day 1, +56.4% off its day-141 low ($13.06).
• H1 2026 showed growth with margin gains plus successful integration of the India and Portugal businesses. On August 18 the company announced forward contracts to acquire up to 5.5 million ordinary shares for incentive-plan purposes, of which 2,835,849 had been acquired.
• The slowest-to-bottom of the clean classic spins (141 days) has become one of the steadiest compounders — five straight monthly gains from the April trough, and now the third-best full-cycle return among the non-speculative names. HOLD, with the recovery long since established and the entry window closed. Parent UL $64.85 (+4.9%).

16. QNITY ELECTRONICS (Q) ⭐⭐⭐ A- — HOLD ⬇️ (rating cut from BUY; grade trimmed within band)

• Current Price: $119.43 (-9.0% in August); +13.7% vs Day 1, +62.4% off its post-spin low ($73.54, day 21). Down 32% from the June 22 all-time closing high of $175.64 with no fundamental deterioration whatsoever.
• Q2 (August 4) was the best print in this report: net sales $1.4B, +22%; adjusted earnings $250M, +53%; adjusted EPS $1.19 against a $0.65 consensus — an 83% beat; ninth consecutive quarter of profitable growth; 28% organic growth in Interconnect Solutions. FY guidance raised to $5.55–5.65B of net sales, $1.675–1.725B of adjusted operating EBITDA and $4.40–4.60 of adjusted EPS. The stock popped 6% premarket to $141.50 and spent the rest of the month giving it back.

⚠️ Why the rating comes down even though the quarter was excellent

Earlier in this cycle this report called Qnity “cheaper than at any point since its spin while earning more” and maintained BUY. The filings — the FY2025 10-K and the Q2 10-Q — support a narrower conclusion than that.

“Volume, not price” is the whole thesis, and it cuts both ways. Qnity’s own disclosure shows realised price falling 1–2% a year in both segments, in both 2024 and 2025 — the two strongest years the semiconductor industry has ever had. The company sits in the layer of the AI value chain with the least pricing power: qualification protects the socket, but the customer sets the price. When the buildout normalizes, that is the layer that gives back the most multiple.

A reverse DCF says the market is paying for 8.0% long-run revenue growth at a flat 30.2% margin — and the four-year record says flat is right: segment margin was 31.3% in 2022 and 31.2% in 2025, having recovered a 2023 destocking in which revenue fell 15% and EBITDA fell 26% (1.7x downside operating leverage). Interconnect gained 3.8 points over that span; Semiconductor Technologies lost 3.4. China is 33% of net sales.

• Grade Change: A- (3.80) → A- (3.58) — the score moves, the band holds. Two markdowns, each charged once: Competitive Position on the pricing decomposition, Financial Profile on the four-year margin record. Strategic Rationale and Acquisition Potential are deliberately unchanged; re-charging the pricing finding to a third dimension would double-count one objection. The evidence changed what we know about the earnings, not whether this is a good business.
• Recommendation: ⭐⭐⭐ HOLD. Target $132; accumulate below ≈$115. At $119.43 the stock sits between those two marks — which is precisely why the rating is HOLD rather than BUY or SELL. The question is not whether Qnity is a good business; the filings settle that it is. It is whether the AI acceleration is a cycle or a step-change, and you are being asked to pay a fair price for the answer.
• (Parent DuPont: $134.59 raw, $44.86 split-adjusted, +30.5% since the spin — DD has now outperformed its own SpinCo (+13.7%) by a widening margin, the most durable RemainCo-wins case in this dataset.)

17. SOLSTICE ADVANCED MATERIALS (SOLS) ⭐⭐⭐⭐ A- — HOLD (first grade: A- 3.63)

• Current Price: $63.39 (+5.4% in August, including +12.8% on August 28); +26.7% vs Day 1, +53.0% off its post-spin low.
• The Element Solutions merger was mutually terminated on August 27. Both boards concluded — “based on constructive feedback from shareholders” — that the two companies serve their holders better standalone. Neither party owes the other any payment: no break fee, no stranded financing cost, no reverse-termination liability, despite a disclosed termination fee of $385M or $513M in specified circumstances. Solstice paired the announcement with a $500M share repurchase authorisation.
• What that restores. July’s downgrade was explicit that this was a thesis change, not a drawdown to buy: the security graded was a clean, high-margin specialty-materials pure-play, and what was being created was a leveraged acquirer integrating a $14.5B target nine months after independence — with pro-forma leverage rising toward ≈3.5x and a $4.685B Goldman bridge commitment. That security no longer exists. The original one does, with FY 2026 guidance (revenue $4.13–4.19B, adjusted EBITDA $1.04–1.06B) intact.

⚠️ Why this is a grade upgrade but not a BUY

The termination was the outcome that standalone analysis had identified as the upside case — the arithmetic of issuing paper at ≈9.4x EV/EBITDA to buy an asset at 26.5x (19.9x after synergies) is what took 22.5% out of the stock over two sessions in July, and unwinding it was worth money. The market paid for it immediately: +12.8% in a single session.

That leaves the shares at $63.39 against a standalone fair value of roughly $61, on a range of $55–69. The upside case landed and the price captured it. At ≈11.2x the midpoint of FY26 adjusted EBITDA guidance, Solstice is no longer discounted.

The three-year record is why the fair value is not higher: adjusted EBITDA margin ran 29.9% → 25.7% → 25.2%, with 2025 EBITDA below 2023 in absolute dollars, and normalized standalone EPS is down 14% since 2023 (24% excluding ConverDyn). 2025 free cash flow was $119M against $546M in 2024, cash conversion falling from 77% of adjusted EBITDA to 46% — though 1H26 already exceeds all of 2025 on operating cash flow, free cash flow is up 45%, and capital expenditure at 169–184% of depreciation is growth spending rather than maintenance, which is also what explains the under-absorbed fixed cost in the margin line.

• Grade Change: First grade for this company — A- (3.63). Solstice has been carried as a completed spinoff without a letter grade since separation in October 2025. An earlier working score of 3.75 came down to 3.63 once the three-year segment history was pulled: the refrigerant margin decline is three years old, not two quarters. An earlier draft had also marked down Strategic Rationale and Management for the price paid for Element Solutions — that was double-counting a single objection, since the purchase price is already reflected in the price a buyer pays today. The price was a valuation input, not a character flaw; the deal is now moot in any case.
• Recommendation: ⭐⭐⭐ HOLD. Target $62. This is a change of direction from earlier in this cycle, when the termination alone was read as restoring a BUY. The termination restored the security; the share price then took the value it was worth. An A- business at fair value is a hold, not a buy. What would take it to A: refrigerant margin stabilising for two consecutive quarters. What would take it down: evidence that the refrigerant decline is structural.
• Element Solutions announces mutual termination of the merger agreement with Solstice Advanced Materials
• Solstice (SOLS) jumps 12.8% on merger exit and $500M buyback
• SEC — Solstice Advanced Materials Form 10-Q, quarter ended June 30, 2026

18. RALLIANT (RAL) ⭐⭐⭐⭐ A- — HOLD (NEW to this report; first grade: A- 3.50)

• Current Price: $61.73 (-5.6% in August); +27.3% vs the $48.49 Day-1 close (June 30, 2025), and +60.8% off its post-spin low of $38.39 on February 5, 2026 — a day-220 trough, the second-latest in the tracked set after Starz.
• Why it is here now: Ralliant separated from Fortive on June 30, 2025 and has been carried in the research universe without ever appearing in a report. It falls inside the window this report’s Part 3 already covers, it now has four years of segment history from the Form 10 plus three quarters of standalone reporting, and it carries a first investment grade. Adding it closes a coverage gap rather than reflecting any new event.
• The business is two businesses stapled together, and only one is working. Sensors and Safety Systems — power-grid monitoring, aerospace and defense ignition systems, precision sensing — earns 28.4% operating margins and grew 11.5% last quarter. Test and Measurement — Tektronix oscilloscopes and the Elektro-Automatik high-power business — earns 2.4% and took a $1.44B goodwill impairment in 2025 on collapsing EV-related demand.
• The long record confirms the split rather than softening it. Sensors is extraordinary but barely grows: a 1.3-point margin band across four years on a +1.3% revenue CAGR. Test & Measurement is more cyclical than any single year showed, with a 20.3% peak margin in 2023 against 2.4% today.
• Valuation is the whole problem. At $61.73 the shares trade at roughly 17.5x EV/EBITDA and 30.9x earnings, and have beaten the S&P by about 12 percentage points annualised since the spin. Put both segments at their best — Sensors at a generous 17x EBIT and Test & Measurement back at its 2023 peak — and the sum of the parts reaches ≈$63, which is where the shares trade. Everything good that could plausibly happen is already in the price.

• Grade Change: First grade — A- (3.50).
• Recommendation: ⭐⭐⭐ HOLD. Target $58. The grade and the rating point opposite ways, and deliberately so — this is the mirror image of Versigent, where a B+ business trades at 7.4x earnings; here an A- business trades at 30.9x. The grade reflects a genuinely excellent Sensors franchise and consistently well-judged capital allocation. The rating reflects that a sum-of-the-parts crediting Sensors with 18x EBIT and a full Test & Measurement recovery still lands below the current price. What would take it to A: Test & Measurement margin recovering into double digits. What would take it down: a second impairment, or evidence that the 2026 recovery was a restocking cycle.
• Parent Fortive (FTV) $58.84, +12.9% since the June 30, 2025 spin — one of the few tracked separations where both halves are comfortably positive.

19. STARZ (STRZ) & LIONSGATE STUDIOS (LION) — PARENT SPLIT

• STRZ: $26.48 (+1.8% in August); +136.4% from reference, +206.1% off its post-spin low ($8.65, day 274). No longer the strongest total return in the tracked set — Sandisk’s addition displaces it by an order of magnitude — but still the best outcome among names this report graded before the fact. HOLD — after a 2.4x, this is a position to manage rather than add to.
• LION: $11.33 (-14.7% in August, the third-worst monthly performer); +39.0% from reference, +102.7% off its day-61 low. Q1 FY27 (August 6): revenue $776.6M, +48% year over year, operating income $25.6M — but a net loss from continuing operations of $(28.8)M, or $(0.10) per diluted share. Revenue growing 48% while the bottom line stays negative is the studio model working and not yet paying; the market marked the loss, not the growth. BUY maintained, with the caveat that profitability, not revenue, is now the thing to underwrite.

20. SANDISK (SNDK) ⭐⭐⭐ B — HOLD (NEW to this report; first grade: B 2.93)

• Current Price: $1,566.70 (+29.0% in August, after a -46.6% July); +3,123.7% vs the $48.60 Day-1 close (February 24, 2025) and +5,189.0% off its post-spin low of $29.62 on April 22, 2025 (day 57).
• ⚠️ Read the return with care. This is the largest outcome in the research universe by a wide margin, and it is a NAND pricing cycle, not a spinoff outcome. Nothing about the separation structure produced it, and the monthly path — -46.6% then +29.0% — is the honest description of what owning it involves. It is included because it separated from Western Digital on February 24, 2025, inside the window Part 3 already covers, and because it now carries a first grade.
• What actually happened: revenue rose 175% in FY2026 while the company shipped only mid-teens percent more bits. Roughly 91% of the growth was price — revenue per gigabyte rose ≈150% in Datacenter and ≈180% in Edge.

Datacenter was 5% of revenue two years ago and is 25% now — the AI infrastructure build arriving in a memory company’s accounts.

The valuation trap

The company lost money in three of the four years for which records exist. Cumulative FY2023–25 operating losses were $6.4B. FY2026 operating income was $12.4B.

At $1,566.70 the shares trade at roughly 21x trailing earnings — which sounds unremarkable until the source of those earnings is priced. A 35% reversion in NAND pricing takes the P/E from ≈21x to ≈49x. A 50% reversion takes it past 110x. Against a three-year average operating income the shares trade at roughly 74x. The multiple looks lowest exactly at the top, which is the oldest trap in commodity investing.

• Grade Change: First grade — B (2.93). A genuinely improved business riding a pricing spike nobody can size.
• Recommendation: ⭐⭐⭐ HOLD. No price target — a target requires a view on NAND pricing two years out, and the honest position is that the cycle is not forecastable at this amplitude. The structural improvement is real: datacenter mix, zero debt, $4.8B of cash. What is not knowable is how much of $12.4B of operating income survives normalization.
• Parent Western Digital (WDC) $450.55, +819.1% since the February 2025 separation — the rare case where both halves compounded enormously, which says the separation was correct and the cycle was extraordinary, in that order.

21. MILLROSE PROPERTIES (MRP) ⭐⭐⭐⭐ — BUY

• Current Price: $30.42 (+8.7% in August, recovering July’s decline); +29.5% vs Day 1, +43.4% off its post-spin low ($21.22, day 31).
• Parent LEN $84.11 (+2.1% in August, -29.8% since the spin) remains the weakest tracked parent over a full cycle. Millrose’s land-bank REIT model is deliberately insulated from the homebuilding cycle (total assets $9.6B, diversifying beyond Lennar), and August restated the case: MRP rose 8.7% while the housing complex stayed weak. The divergence between MRP +29.5% and LEN -29.8% — a 59-point spread over eighteen months — is the entire point of the structure. BUY.

Part 4: OUTLOOK & UPCOMING CATALYST CALENDAR

September 2026:

• ⚠️ Early-to-mid September: Corteva record-date and distribution-ratio announcement expected. This is the single most time-sensitive item in the report — on an October 1 distribution the record date should fall in mid-September, and as of the pricing date it has not been set. If nothing is announced by mid-September, treat the October 1 date as at risk.
• September 10: Gentherm special meeting — the Share Issuance and Charter Amendment proposals, the only remaining Gentherm shareholder approvals for the Modine Performance Technologies RMT
• September 10: Mobility Global’s first dividend payable ($0.06/share)
• September: Flex SpinCo name reveal — promised for September and already overdue relative to the original guidance
• September 29: Vylor exchange offers expire (extended from September 3)
• Late September / October: MSG Rangers Form 10 effectiveness and record date, ahead of an end-of-October distribution
• Post-spin windows to watch: ADIG (past its day-14 trough), MBGL (past its day-40 trough), OCTV (pattern complete). HONA is a separate case — its day-38 low was an information low, not a forced-selling one, so it is a buy on the re-underwritten valuation rather than on the structural pattern

Q4 2026:

• ⚠️ October 1: Corteva → Vylor distribution — the largest separation of the year and the top-graded name on the board
• End of October: MSG Sports → MSG Rangers (MSGR); MSGS becomes MSGK
• By year-end: Modine/Gentherm Performance Technologies RMT close; Barrick North American Barrick IPO (10–15% float); Adaptive Biotechnologies separation-path decision; KDP “operational readiness” milestone for Global Coffee
• ⚠️ New Fortress Energy → BrazilCo/CoreCo: the Q3 target has lapsed; watch for a revised timetable
• Early November: HONA Q3 — the single most consequential earnings item in this report. It settles the cash-conversion question (1H free cash flow was $86M, flattered by $344M of receivables sold) and whether the casting constraint is easing; watch for a second guidance cut, 2H free cash flow below $1.0B, rising receivables factoring, or defense passing 45% of segment sales
• First standalone Q3 prints for MBGL, MFP and ADIG

2027:

• January 4: KBR → Trinzic distribution (firm date — but no Form 10 on file as of August 31)
• Q1: Eaton Mobility + Dana RMT close; Flex Power & Cloud Infrastructure; Genuine Parts Global Industrial; International Paper EMEA; Keurig Dr Pepper Global Coffee (early 2027)
• By April: Medtronic MiniMed split-off (loosened from year-end 2026)
• Mid: Comcast/NBCUniversal; Unilever/McCormick close; L3Harris Missile Solutions IPO
• Q2–Q3: Textron Industrial (sale or spin)
• H2: McKesson Medical-Surgical; J&J DePuy Synthes (if a spin); HF Sinclair Lubricants & Specialties; Solventum Health Information Systems (structure TBD)

Watch items / status changes this cycle:

• ⬇️ HONA downgraded A (4.05) → B+ (3.20) on six years of segment margin history, not on the guidance cut; rating STRONG BUY → BUY, target $195 — the grade and the rating deliberately point opposite ways
• ⬇️ FDXF downgraded A- (3.80) → B+ (3.15) on the FY2026 10-K and calendar recast; rating BUY → HOLD, target $108
• ⬇️ Q trimmed A- (3.80) → A- (3.58) on realised-price disclosure; rating BUY → HOLD, target $132
• 🆕 SOLS takes a first grade of A- (3.63) after the August 27 merger termination; rating HOLD, target $62
• 🆕 VGNT takes a first grade of B+ (3.20); rating BUY, target $62
• 🆕 RAL (A- 3.50, HOLD) and SNDK (B 2.93, HOLD) added to Part 3 coverage
• ⬆️ MSG Sports → MSGR upgraded C+ → B; Form 10 public, ticker set, end-October target
• ⬆️ Barrick upgraded B → B+ on the August 9 Newmont settlement and IPO consent
• ⬆️ Modine/Gentherm upgraded B → B+ on S-4 effectiveness and a September 10 vote date
• ⬆️ OCTV upgraded HOLD → BUY — the confirmed higher low this report was waiting for
• ✅ Corteva/Vylor’s provisional flag lifted — $5.58B of pro-forma debt at 2.23x gross on a 25.3% margin; A- (3.80) maintained
• ⚠️ Corteva’s record date, ratio and ticker are still blank four weeks from the target date
• ⚠️ KBR/Trinzic has no Form 10 on file four months from a “firm” January 4 date
• ⚠️ Medtronic loosened the MiniMed timing to “before fiscal year-end” (April 2027)
• ⚠️ KDP still has no Global Coffee CEO after three months of searching
• ⚠️ J&J’s DePuy decision is ≈3 months overdue
• 🆕 Solventum → Health Information Systems (announced Aug 5) — the month’s significant new separation, structure undecided

APPENDIX A: COMPLETE SPINOFF LIST (August 2026)

Sort: by investment grade (highest first), matching the Part 2 ranking; ungraded micro-caps last.

Completed / now-trading spinoffs and their full post-spin performance (including low-recovery analysis) are tracked in Part 3, Tables A–D — not duplicated here.

Completed This Cycle (moved to Part 3): ADI Global Distribution (ADIG, Aug 3–4).

Removed / Reclassified / Paused / Canceled:

• ⚠️ Kraft Heinz → 2-way split: Paused indefinitely — shelved (prior)
• ⚠️ Teleflex → NewCo: Converted to outright sales (≈$2.03B) — removed (prior)
• ABB → ABB Robotics: SoftBank sale ($5.375B) — removed (prior)
• WBD → Discovery Global: Shelved — Paramount acquiring WBD (prior)
• Topgolf Callaway: Converted to a sale (prior)
• CSL Seqirus: Postponed indefinitely (prior)
• Trump Media → Truth Social: Paused June 10, 2026
• Microsoft → Xbox: Under review / rumor only — not tracked
• Non-US separations monitored but not individually tracked: SoftBank → Roze, Associated British Foods → Primark, Siemens Energy → Industrial Turbines, Baidu → Kunlunxin, Jollibee → International, Evotec → Just Biologics, Alibaba (HKEX-approved), UPM-Kymmene → WISA Group (Oct 31, 2026, Helsinki)

APPENDIX B: SPINOFF STRUCTURE REFERENCE

Not all corporate spinoffs are structured the same way. The sections above use short tags to label each transaction by its primary legal/mechanical structure, with an optional set of “orthogonal features” that can modify any primary structure. This appendix defines those tags.

Primary Structures (mutually exclusive — the core mechanic)

Orthogonal Features (can apply to any primary structure; multiple possible)

Report Generated: August 31, 2026 Pricing: All stock prices as of August 31, 2026 close (verified daily data via yfinance). Next Update Recommended: Late September / early October 2026 — after the Gentherm vote (September 10), the Corteva record date (expected mid-September), the September 29 Vylor exchange expiration and the October 1 Vylor distribution, and ahead of the MSG Rangers end-October spin. The Corteva/Vylor separation is the single highest-value event in the next edition: it is the largest transaction of the year, the top-graded name on the board, and the first spin this report has graded on fully disclosed separation leverage before the fact rather than after it. Methodology: Built primarily from company IR websites, SEC filings (Form 10 / 10-12B and amendments, 8-K, S-1, S-4, 10-Q, 10-K, DEF 14A), press releases, and financial news, supplemented by “upcoming spinoffs” searches and backward-looking searches for announcements 24-36 months ago. Grades, scores, ratings and price targets in Part 3 are reconciled to the standing company profiles, which carry the full primary-source workups for the deeply-analyzed names (Honeywell Aerospace, Mobility Global, Solstice, FedEx Freight, Qnity, Versigent, Ralliant, Sandisk and Corteva/Vylor); where a profile proposed a grade change “effective with the next published report,” this is that report and the change is carried here. The prior report (July 31, 2026) is the baseline. Community trackers (The Zen of Investing, Inside Arbitrage, StockSpinoffs.com) used as secondary corroboration and completeness checks — this cycle they surfaced the Solventum, Vivani and UPM-Kymmene additions and the MSG Rangers timetable. Primary filings were pulled directly from EDGAR for the four names where a document became available this cycle: Vylor’s Form 10-12B/A and Corteva’s exchange-offer and notes-issuance 8-Ks; MSGS Spinco’s Form 10; Mobility Global’s Q2 8-K; and Honeywell Aerospace’s Q2 8-K. Completed-spinoff prices and post-spin lows computed from verified daily OHLC (yfinance). The Investment Scorecard applies the five-dimension weighted framework (Financial 25%, Competitive 25%, Strategic 20%, Management 20%, Acquisition 10%; 1-5 per dimension) mapped to letter grades per the Spinoff Investment Analysis Skill methodology. Source: Spinoff Investment Analysis Skill v4.0

SOURCES

Completed Spinoffs — August 2026

• ADI Global Distribution completes spin-off from Resideo and begins trading on the NYSE
• Resideo Technologies completes spin-off of ADI Global Distribution
• Resideo — Board sets record date (Jul 20) and August 3 distribution for ADI Global

Upcoming Spinoffs — Primary Sources

• SEC — Vylor Inc. Form 10-12B/A information statement (August 14, 2026)
• SEC — Corteva 8-K: early tender results and extension of the Vylor exchange offers (August 20, 2026)
• SEC — Corteva / EIDP 8-K: Vylor $1.1B senior notes offering (August 31, 2026)
• SEC — MSGS Spinco, Inc. (MSG Rangers Corp.) Form 10 information statement (August 14, 2026)
• MSG Sports — Publicly files Form 10 for the proposed spin-off of the Rangers business from the Knicks business
• Barrick — Advances IPO of North American gold assets, announces executive appointments
• BNN Bloomberg — Barrick settles Nevada dispute with Newmont; $1.95B top-up clears path for North American IPO (August 10, 2026)
• SEC — Gentherm Form S-4 (Modine Performance Technologies combination)
• Modine — Gentherm and Modine’s Performance Technologies business to combine
• Solventum — Announces intent to separate its Health Information Systems business (August 5, 2026)
• SEC — Solventum Form 8-K (August 5, 2026)
• Flex — Announces leadership teams for Flex and the planned Cloud and Power Infrastructure spin-off
• Keurig Dr Pepper — Reports Q2 results and reaffirms 2026 guidance (August 6, 2026)
• SEC — KBR Form 8-K, Q2 2026 results (MTS / STS segment detail)
• StockSpinoffs — KBR sets January 4, 2027 for the Trinzic spinoff (August 18, 2026)
• Oil & Gas Journal — HF Sinclair inks supply deals amid pending segment spinoff and refinery closure
• Eaton — Mobility Group to combine with Dana in a Reverse Morris Trust
• The Grocer — CMA opens probe into McCormick’s acquisition of Unilever Foods
• The Grocer — Unilever to carve out Colman’s ahead of the McCormick deal

Completed-Spinoff Developments

• SEC — Honeywell Aerospace Form 8-K, Q2 2026 earnings release
• Quartz — Honeywell Aerospace Q2 2026 earnings miss, cuts full-year outlook
• TechTimes — Honeywell Aerospace stock plunges as casting shortage starves aftermarket
• Mobility Global — Reports second quarter 2026 financial results
• SEC — Mobility Global Form 8-K, Q2 2026
• Element Solutions — Announces mutual termination of the merger agreement with Solstice Advanced Materials (August 27, 2026)
• Solstice (SOLS) jumps 12.8% on merger exit and $500M buyback
• BusinessWire — Qnity reports Q2 2026 results, raises full-year guidance
• BusinessWire — Versigent reports second quarter 2026 results
• CNBC — Versant (VSNT) Q2 2026 earnings
• PR Newswire — Atrium Therapeutics reports Q2 2026 financial results (IND clearance, Corventis launch, BMS milestone)
• GlobeNewswire — Midera Food Processing reports Q2 2026 results in its first report as an independent public company
• Middleby — Reports second quarter results (August 11, 2026)
• ADI — Announces second quarter 2026 financial results
• Motley Fool — Why Resideo Technologies stock is plummeting this week (August 14, 2026)
• Yahoo Finance — Aptiv shares decline as weak guidance overshadows a second-quarter earnings beat
• SEC — First Tracks Biotherapeutics Form 8-K, Q2 2026
• SEC — Lionsgate Studios Form 10-Q, quarter ended June 30, 2026
• Investing.com — Medtronic Q1 FY27: 13.7% organic growth lifts guidance; MiniMed separation reaffirmed
• StockTitan — Magnum Ice Cream share purchases for long-term incentive plans
• SEC — FedEx Freight Holding Company Form 10-K (fiscal year ended May 31, 2026)

Online Community Corroborative Sources

• The Zen of Investing - Upcoming Spinoffs
• Inside Arbitrage - Spinoffs
• StockSpinoffs.com - Upcoming Spinoffs

DISCLAIMER

This report is for informational and educational purposes only. Not investment advice. Spinoff transactions are subject to change, delay, or cancellation — this cycle alone saw a $14.5B announced acquisition by a recently spun company mutually terminated seven weeks after it was signed (Solstice / Element Solutions), a newly independent company cut the guidance it had set at separation within six weeks (Honeywell Aerospace), a company loosen the timing of an already-announced separation (Medtronic / MiniMed), and one long-guided decision remain unresolved for a second consecutive report (J&J / DePuy Synthes). Stock prices referenced are as of the August 31, 2026 close (verified daily data via yfinance).

Where a parent has undergone a corporate action that distorts comparison, this is footnoted and the affected figures are shown adjusted or marked “n/m” — this edition adds Resideo, whose historical quotes in adjusted price series were retroactively scaled by a 1.437 factor on August 4 to reflect the ADI distribution; the Table D baseline uses Resideo’s actual first regular-way ex-distribution close of $26.17. Honeywell’s 3-way breakup plus 1-for-2 reverse split and DuPont’s 1-for-3 reverse split continue to be footnoted as in prior editions.

Corrections recorded in this edition. Two arise from Mobility Global’s first standalone quarter rather than any sourcing error: the dividend estimate was too low (the declared $0.06 quarterly dividend is roughly double the $0.115–$0.187 annual range July modeled from the stated payout policy), and the 2026 free-cash-flow projection was too high (July assumed ≈$496–507M; 1H26 actual was $177M on $57M of separation costs). The second is a calendar effect rather than a reset of earning power — FY2025 free cash flow of $461M remains the right valuation basis — so July’s total-distribution and capital-allocation tables are better read as a 2027 case.

Three grade changes in this edition were triggered by primary-source evidence that already existed and had not been examined, not by anything that happened to the businesses, and the distinction matters to a reader deciding whether something changed at the company or in the analysis. Honeywell Aerospace’s A → B+ rests on six years of Honeywell segment disclosure showing margin declining in four consecutive periods, most of it before the precision-casting constraint management cited; an earlier read in this same cycle attributed the decline to castings and set a HOLD, and both are superseded here — the grade falls two notches and the rating rises to BUY. FedEx Freight’s A- → B+ rests on the FY2026 10-K and calendar-year recast, which supplied nine years of operating-ratio history the pre-spin grade never had. Qnity’s A- (3.80) → A- (3.58) rests on realised-price disclosure in its own filings. In all three cases the businesses did what they were expected to do; the analysis had not been tested against the long record.

Several names in this report are graded on incomplete information and are flagged as such: Corteva/Vylor’s record date, distribution ratio and ticker remain blank four weeks from its target distribution date; KBR/Trinzic has no registration statement on file four months from a stated firm date; Solventum has not chosen a separation structure; and the Modine/Gentherm S-4 presents combined pro-formas without a standalone SpinCo margin or separation-debt disclosure. Newly announced transactions (Solventum, Vivani, UPM-Kymmene) are early-stage and their terms may change materially. Always conduct your own due diligence and consult with financial advisors before making investment decisions. Past spinoff performance does not guarantee future results.